Adherence to adjuvant hormonal therapy among breast cancer survivors in clinical practice: a systematic review
Adjuvant hormonal therapy significantly improves long-term survival of breast cancer patients with hormone receptor-positive disease. Despite the proven clinical efficacy of tamoxifen and aromatase inhibitors, many breast cancer survivors either fail to take the correct dosage at the prescribed freq...
Uloženo v:
| Vydáno v: | Breast cancer research and treatment Ročník 134; číslo 2; s. 459 - 478 |
|---|---|
| Hlavní autoři: | , , , , |
| Médium: | Journal Article |
| Jazyk: | angličtina |
| Vydáno: |
Boston
Springer US
01.07.2012
Springer Springer Nature B.V |
| Témata: | |
| ISSN: | 0167-6806, 1573-7217, 1573-7217 |
| On-line přístup: | Získat plný text |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|
| Abstract | Adjuvant hormonal therapy significantly improves long-term survival of breast cancer patients with hormone receptor-positive disease. Despite the proven clinical efficacy of tamoxifen and aromatase inhibitors, many breast cancer survivors either fail to take the correct dosage at the prescribed frequency (adherence) or discontinue therapy (persistence). This systematic review aims to: (1) determine the prevalence of adherence and persistence to adjuvant hormonal therapy among breast cancer survivors in clinical practice, and (2) identify correlates of adherence and persistence. We searched Medline, PubMed, PsycINFO, and CINAHL for studies that measured rates and/or correlates of adherence and/or persistence to adjuvant hormonal therapy. Studies were reviewed in a multi-step process: (1) the lead author screened titles and abstracts of all potentially eligible studies; (2) each coauthor reviewed a random 5 % sample of abstracts; and (3) two sets of coauthors each reviewed half of all “maybe” abstracts. Any disagreements were discussed until consensus was reached. Twenty-nine studies met inclusion criteria. Prevalence of adherence ranged from 41 to 72 % and discontinuation (i.e., nonpersistence) ranged from 31 to 73 %, measured at the end of 5 years of treatment. Extremes of age (older or younger), increasing out-of-pocket costs, follow-up care with a general practitioner (vs. oncologist), higher CYP2D6 activity, switching from one form of therapy to another, and treatment side effects were negatively associated with adherence and/or persistence. Taking more medications at baseline, referral to an oncologist, and earlier year at diagnosis were positively associated with adherence and/or persistence. Adherence and persistence to adjuvant hormonal therapy among breast cancer survivors is suboptimal. Many of the correlates of adherence and persistence studied to date are not modifiable. Our review reveals a critical need for further research on modifiable factors associated with adherence to adjuvant hormonal therapy, and the development of behavioral interventions to improve adherence in this population. |
|---|---|
| AbstractList | Adjuvant hormonal therapy significantly improves long-term survival of breast cancer patients with hormone receptor-positive disease. Despite the proven clinical efficacy of tamoxifen and aromatase inhibitors, many breast cancer survivors either fail to take the correct dosage at the prescribed frequency (adherence) or discontinue therapy (persistence). This systematic review aims to: (1) determine the prevalence of adherence and persistence to adjuvant hormonal therapy among breast cancer survivors in clinical practice, and (2) identify correlates of adherence and persistence. We searched Medline, PubMed, PsycINFO, and CINAHL for studies that measured rates and/or correlates of adherence and/or persistence to adjuvant hormonal therapy. Studies were reviewed in a multistep process: (1) the lead author screened titles and abstracts of all potentially eligible studies; (2) each coauthor reviewed a random 5% sample of abstracts; and (3) two sets of coauthors each reviewed half of all "maybe" abstracts. Any disagreements were discussed until consensus was reached. Twenty-nine studies met inclusion criteria. Prevalence of adherence ranged from 41 to 72% and discontinuation (i.e., nonpersistence) ranged from 31 to 73%, measured at the end of 5 years of treatment. Extremes of age (older or younger), increasing out-of-pocket costs, follow-up care with a general practitioner (vs. oncologist), higher CYP2D6 activity, switching from one form of therapy to another, and treatment side effects were negatively associated with adherence and/or persistence. Taking more medications at baseline, referral to an oncologist, and earlier year at diagnosis were positively associated with adherence and/or persistence. Adherence and persistence to adjuvant hormonal therapy among breast cancer survivors is suboptimal. Many of the correlates of adherence and persistence studied to date are not modifiable. Our review reveals a critical need for further research on modifiable factors associated with adherence to adjuvant hormonal therapy, and the development of behavioral interventions to improve adherence in this population. Keywords Adherence * Adjuvant hormonal therapy * Systematic review * Survivorship Adjuvant hormonal therapy significantly improves long-term survival of breast cancer patients with hormone receptor-positive disease. Despite the proven clinical efficacy of tamoxifen and aromatase inhibitors, many breast cancer survivors either fail to take the correct dosage at the prescribed frequency (adherence) or discontinue therapy (persistence). This systematic review aims to: (1) determine the prevalence of adherence and persistence to adjuvant hormonal therapy among breast cancer survivors in clinical practice, and (2) identify correlates of adherence and persistence. We searched Medline, PubMed, PsycINFO, and CINAHL for studies that measured rates and/or correlates of adherence and/or persistence to adjuvant hormonal therapy. Studies were reviewed in a multi-step process: (1) the lead author screened titles and abstracts of all potentially eligible studies; (2) each coauthor reviewed a random 5 % sample of abstracts; and (3) two sets of coauthors each reviewed half of all "maybe" abstracts. Any disagreements were discussed until consensus was reached. Twenty-nine studies met inclusion criteria. Prevalence of adherence ranged from 41 to 72 % and discontinuation (i.e., nonpersistence) ranged from 31 to 73 %, measured at the end of 5 years of treatment. Extremes of age (older or younger), increasing out-of-pocket costs, follow-up care with a general practitioner (vs. oncologist), higher CYP2D6 activity, switching from one form of therapy to another, and treatment side effects were negatively associated with adherence and/or persistence. Taking more medications at baseline, referral to an oncologist, and earlier year at diagnosis were positively associated with adherence and/or persistence. Adherence and persistence to adjuvant hormonal therapy among breast cancer survivors is suboptimal. Many of the correlates of adherence and persistence studied to date are not modifiable. Our review reveals a critical need for further research on modifiable factors associated with adherence to adjuvant hormonal therapy, and the development of behavioral interventions to improve adherence in this population.Adjuvant hormonal therapy significantly improves long-term survival of breast cancer patients with hormone receptor-positive disease. Despite the proven clinical efficacy of tamoxifen and aromatase inhibitors, many breast cancer survivors either fail to take the correct dosage at the prescribed frequency (adherence) or discontinue therapy (persistence). This systematic review aims to: (1) determine the prevalence of adherence and persistence to adjuvant hormonal therapy among breast cancer survivors in clinical practice, and (2) identify correlates of adherence and persistence. We searched Medline, PubMed, PsycINFO, and CINAHL for studies that measured rates and/or correlates of adherence and/or persistence to adjuvant hormonal therapy. Studies were reviewed in a multi-step process: (1) the lead author screened titles and abstracts of all potentially eligible studies; (2) each coauthor reviewed a random 5 % sample of abstracts; and (3) two sets of coauthors each reviewed half of all "maybe" abstracts. Any disagreements were discussed until consensus was reached. Twenty-nine studies met inclusion criteria. Prevalence of adherence ranged from 41 to 72 % and discontinuation (i.e., nonpersistence) ranged from 31 to 73 %, measured at the end of 5 years of treatment. Extremes of age (older or younger), increasing out-of-pocket costs, follow-up care with a general practitioner (vs. oncologist), higher CYP2D6 activity, switching from one form of therapy to another, and treatment side effects were negatively associated with adherence and/or persistence. Taking more medications at baseline, referral to an oncologist, and earlier year at diagnosis were positively associated with adherence and/or persistence. Adherence and persistence to adjuvant hormonal therapy among breast cancer survivors is suboptimal. Many of the correlates of adherence and persistence studied to date are not modifiable. Our review reveals a critical need for further research on modifiable factors associated with adherence to adjuvant hormonal therapy, and the development of behavioral interventions to improve adherence in this population. Adjuvant hormonal therapy significantly improves long-term survival of breast cancer patients with hormone receptor-positive disease. Despite the proven clinical efficacy of tamoxifen and aromatase inhibitors, many breast cancer survivors either fail to take the correct dosage at the prescribed frequency (adherence) or discontinue therapy (persistence). This systematic review aims to: (1) determine the prevalence of adherence and persistence to adjuvant hormonal therapy among breast cancer survivors in clinical practice, and (2) identify correlates of adherence and persistence. We searched Medline, PubMed, PsycINFO, and CINAHL for studies that measured rates and/or correlates of adherence and/or persistence to adjuvant hormonal therapy. Studies were reviewed in a multi-step process: (1) the lead author screened titles and abstracts of all potentially eligible studies; (2) each coauthor reviewed a random 5 % sample of abstracts; and (3) two sets of coauthors each reviewed half of all "maybe" abstracts. Any disagreements were discussed until consensus was reached. Twenty-nine studies met inclusion criteria. Prevalence of adherence ranged from 41 to 72 % and discontinuation (i.e., nonpersistence) ranged from 31 to 73 %, measured at the end of 5 years of treatment. Extremes of age (older or younger), increasing out-of-pocket costs, follow-up care with a general practitioner (vs. oncologist), higher CYP2D6 activity, switching from one form of therapy to another, and treatment side effects were negatively associated with adherence and/or persistence. Taking more medications at baseline, referral to an oncologist, and earlier year at diagnosis were positively associated with adherence and/or persistence. Adherence and persistence to adjuvant hormonal therapy among breast cancer survivors is suboptimal. Many of the correlates of adherence and persistence studied to date are not modifiable. Our review reveals a critical need for further research on modifiable factors associated with adherence to adjuvant hormonal therapy, and the development of behavioral interventions to improve adherence in this population.[PUBLICATION ABSTRACT] Adjuvant hormonal therapy significantly improves long-term survival of breast cancer patients with hormone receptor-positive disease. Despite the proven clinical efficacy of tamoxifen and aromatase inhibitors, many breast cancer survivors either fail to take the correct dosage at the prescribed frequency (adherence) or discontinue therapy (persistence). This systematic review aims to: (1) determine the prevalence of adherence and persistence to adjuvant hormonal therapy among breast cancer survivors in clinical practice, and (2) identify correlates of adherence and persistence. We searched Medline, PubMed, PsycINFO, and CINAHL for studies that measured rates and/or correlates of adherence and/or persistence to adjuvant hormonal therapy. Studies were reviewed in a multi-step process: (1) the lead author screened titles and abstracts of all potentially eligible studies; (2) each coauthor reviewed a random 5 % sample of abstracts; and (3) two sets of coauthors each reviewed half of all "maybe" abstracts. Any disagreements were discussed until consensus was reached. Twenty-nine studies met inclusion criteria. Prevalence of adherence ranged from 41 to 72 % and discontinuation (i.e., nonpersistence) ranged from 31 to 73 %, measured at the end of 5 years of treatment. Extremes of age (older or younger), increasing out-of-pocket costs, follow-up care with a general practitioner (vs. oncologist), higher CYP2D6 activity, switching from one form of therapy to another, and treatment side effects were negatively associated with adherence and/or persistence. Taking more medications at baseline, referral to an oncologist, and earlier year at diagnosis were positively associated with adherence and/or persistence. Adherence and persistence to adjuvant hormonal therapy among breast cancer survivors is suboptimal. Many of the correlates of adherence and persistence studied to date are not modifiable. Our review reveals a critical need for further research on modifiable factors associated with adherence to adjuvant hormonal therapy, and the development of behavioral interventions to improve adherence in this population. Adjuvant hormonal therapy significantly improves long-term survival of breast cancer patients with hormone receptor-positive disease. Despite the proven clinical efficacy of tamoxifen and aromatase inhibitors, many breast cancer survivors either fail to take the correct dosage at the prescribed frequency (adherence) or discontinue therapy (persistence). This systematic review aims to: (1) determine the prevalence of adherence and persistence to adjuvant hormonal therapy among breast cancer survivors in clinical practice, and (2) identify correlates of adherence and persistence. We searched Medline, PubMed, PsycINFO, and CINAHL for studies that measured rates and/or correlates of adherence and/or persistence to adjuvant hormonal therapy. Studies were reviewed in a multistep process: (1) the lead author screened titles and abstracts of all potentially eligible studies; (2) each coauthor reviewed a random 5% sample of abstracts; and (3) two sets of coauthors each reviewed half of all "maybe" abstracts. Any disagreements were discussed until consensus was reached. Twenty-nine studies met inclusion criteria. Prevalence of adherence ranged from 41 to 72% and discontinuation (i.e., nonpersistence) ranged from 31 to 73%, measured at the end of 5 years of treatment. Extremes of age (older or younger), increasing out-of-pocket costs, follow-up care with a general practitioner (vs. oncologist), higher CYP2D6 activity, switching from one form of therapy to another, and treatment side effects were negatively associated with adherence and/or persistence. Taking more medications at baseline, referral to an oncologist, and earlier year at diagnosis were positively associated with adherence and/or persistence. Adherence and persistence to adjuvant hormonal therapy among breast cancer survivors is suboptimal. Many of the correlates of adherence and persistence studied to date are not modifiable. Our review reveals a critical need for further research on modifiable factors associated with adherence to adjuvant hormonal therapy, and the development of behavioral interventions to improve adherence in this population. Adjuvant hormonal therapy significantly improves long-term survival of breast cancer patients with hormone receptor-positive disease. Despite the proven clinical efficacy of tamoxifen and aromatase inhibitors, many breast cancer survivors either fail to take the correct dosage at the prescribed frequency (adherence) or discontinue therapy (persistence). This systematic review aims to: (1) determine the prevalence of adherence and persistence to adjuvant hormonal therapy among breast cancer survivors in clinical practice, and (2) identify correlates of adherence and persistence. We searched Medline, PubMed, PsycINFO, and CINAHL for studies that measured rates and/or correlates of adherence and/or persistence to adjuvant hormonal therapy. Studies were reviewed in a multi-step process: (1) the lead author screened titles and abstracts of all potentially eligible studies; (2) each coauthor reviewed a random 5 % sample of abstracts; and (3) two sets of coauthors each reviewed half of all “maybe” abstracts. Any disagreements were discussed until consensus was reached. Twenty-nine studies met inclusion criteria. Prevalence of adherence ranged from 41 to 72 % and discontinuation (i.e., nonpersistence) ranged from 31 to 73 %, measured at the end of 5 years of treatment. Extremes of age (older or younger), increasing out-of-pocket costs, follow-up care with a general practitioner (vs. oncologist), higher CYP2D6 activity, switching from one form of therapy to another, and treatment side effects were negatively associated with adherence and/or persistence. Taking more medications at baseline, referral to an oncologist, and earlier year at diagnosis were positively associated with adherence and/or persistence. Adherence and persistence to adjuvant hormonal therapy among breast cancer survivors is suboptimal. Many of the correlates of adherence and persistence studied to date are not modifiable. Our review reveals a critical need for further research on modifiable factors associated with adherence to adjuvant hormonal therapy, and the development of behavioral interventions to improve adherence in this population. |
| Audience | Academic |
| Author | Bluethmann, Shirley M. Murphy, Caitlin C. Carpentier, Melissa Y. Bartholomew, L. Kay Vernon, Sally W. |
| Author_xml | – sequence: 1 givenname: Caitlin C. surname: Murphy fullname: Murphy, Caitlin C. email: caitlin.c.murphy@uth.tmc.edu organization: Center for Health Promotion and Prevention Research, The University of Texas School of Public Health – sequence: 2 givenname: L. Kay surname: Bartholomew fullname: Bartholomew, L. Kay organization: Center for Health Promotion and Prevention Research, The University of Texas School of Public Health – sequence: 3 givenname: Melissa Y. surname: Carpentier fullname: Carpentier, Melissa Y. organization: Center for Health Promotion and Prevention Research, The University of Texas School of Public Health – sequence: 4 givenname: Shirley M. surname: Bluethmann fullname: Bluethmann, Shirley M. organization: Center for Health Promotion and Prevention Research, The University of Texas School of Public Health – sequence: 5 givenname: Sally W. surname: Vernon fullname: Vernon, Sally W. organization: Center for Health Promotion and Prevention Research, The University of Texas School of Public Health |
| BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=26200810$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/22689091$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9kk-P0zAQxSO0iO0ufAAuyBICccnicRI75oBUrfgnrcQFzpbrTlpXiV1sp6jfHkctS7sClEPk-PdmMm_eVXHhvMOieA70BigVbyPQppYlBVYygLpsHhUzaERVCgbiophR4KLkLeWXxVWMG0qpFFQ-KS4Z462kEmaFmy_XGNAZJMkTvdyMO-0SWfsweKd7kvKt3u6JzscVWQTUMRGjMx9IHMPO7nyIxDpieuusyYpt0CZZg--IJnEfEw46H0nAncWfT4vHne4jPju-r4vvHz98u_1c3n399OV2flcazutUokTIkxnRgQSzELBgIAXWSJtOdBo6QEorSnnViboS0kiQTSslA806vqTVdfH-UHc7LgZcGnQp6F5tgx102CuvrTq_cXatVn6nKk4Fa3ku8OZYIPgfI8akBhsN9r126MeogDLBRcuhyejLB-jGjyGbN1EVBRDylFrpHpV1nc99zVRUzauG17Vg9dT25i9UfpY4WJO339n8_Uzw-kSwRt2ndfT9mKx38Rx8cerIvRW_o5CBV0dAx7zHLuQl2_iH44zSFiZr4cCZ4GMM2N0jQNUUS3WIpcqxVFMs1TS8eKAxNunpH_N4tv-vkh2UMXdxKwyn5v5L9AvMxvPs |
| CODEN | BCTRD6 |
| CitedBy_id | crossref_primary_10_2147_BCTT_S311445 crossref_primary_10_1007_s12094_018_1950_0 crossref_primary_10_1016_j_sapharm_2016_08_004 crossref_primary_10_1186_s12912_016_0130_1 crossref_primary_10_1093_tbm_ibae066 crossref_primary_10_1111_ecc_13722 crossref_primary_10_1016_j_sapharm_2021_12_004 crossref_primary_10_1111_ecc_13721 crossref_primary_10_1093_ptj_pzx069 crossref_primary_10_1016_j_ygyno_2020_08_015 crossref_primary_10_1016_S0140_6736_13_61235_0 crossref_primary_10_1111_ecc_13729 crossref_primary_10_2147_PPA_S319239 crossref_primary_10_1186_s13058_017_0837_2 crossref_primary_10_1016_j_breast_2025_104552 crossref_primary_10_1016_j_clbc_2021_01_007 crossref_primary_10_1200_JCO_2016_67_4184 crossref_primary_10_1007_s10549_018_4676_3 crossref_primary_10_1177_20533691221122358 crossref_primary_10_1002_pon_4931 crossref_primary_10_1186_s12905_018_0522_3 crossref_primary_10_1111_bjhp_12274 crossref_primary_10_1016_S0007_4551_20_30050_3 crossref_primary_10_1007_s00432_022_04376_5 crossref_primary_10_1007_s10549_018_4774_2 crossref_primary_10_5812_jamm_120371 crossref_primary_10_1186_1471_2407_14_397 crossref_primary_10_1007_s10549_017_4346_x crossref_primary_10_2340_1651_226X_2024_40575 crossref_primary_10_1186_s13063_020_04397_w crossref_primary_10_1007_s12325_022_02221_2 crossref_primary_10_1186_s12911_017_0436_2 crossref_primary_10_1016_j_breast_2014_11_006 crossref_primary_10_1016_j_conctc_2022_100898 crossref_primary_10_1002_pon_4702 crossref_primary_10_2147_PPA_S368636 crossref_primary_10_1093_jnci_djac062 crossref_primary_10_1111_bjhp_12266 crossref_primary_10_1007_s10238_023_01261_4 crossref_primary_10_1038_s41523_023_00591_6 crossref_primary_10_1016_j_clbc_2021_09_012 crossref_primary_10_1177_17588359231152845 crossref_primary_10_1016_j_ejon_2014_11_003 crossref_primary_10_3390_curroncol32040192 crossref_primary_10_1111_ecc_13749 crossref_primary_10_1007_s11864_018_0541_1 crossref_primary_10_1200_JCO_2014_59_3673 crossref_primary_10_1200_JCO_2013_51_7367 crossref_primary_10_1245_s10434_020_09432_3 crossref_primary_10_1007_s10549_020_05591_9 crossref_primary_10_1016_j_breast_2025_104416 crossref_primary_10_3390_cancers16122193 crossref_primary_10_1111_jep_13373 crossref_primary_10_1016_j_breast_2017_08_003 crossref_primary_10_1080_07347332_2021_1955318 crossref_primary_10_1007_s11096_023_01609_6 crossref_primary_10_1016_j_jcbs_2022_07_002 crossref_primary_10_1038_s41523_024_00708_5 crossref_primary_10_1002_cncr_28084 crossref_primary_10_1007_s11864_024_01253_w crossref_primary_10_1016_j_breast_2016_07_022 crossref_primary_10_1007_s00520_017_3678_8 crossref_primary_10_1111_jcpt_12569 crossref_primary_10_1186_s12916_019_1252_6 crossref_primary_10_1002_cncr_34409 crossref_primary_10_1111_jnu_12471 crossref_primary_10_1111_ddg_15809 crossref_primary_10_1007_s10549_023_07029_4 crossref_primary_10_1007_s10549_016_3803_2 crossref_primary_10_1016_j_radonc_2017_02_019 crossref_primary_10_1007_s10549_020_05920_y crossref_primary_10_1007_s10549_023_06992_2 crossref_primary_10_1016_j_breastdis_2014_07_015 crossref_primary_10_1007_s10549_017_4561_5 crossref_primary_10_1002_cncr_32051 crossref_primary_10_1007_s11864_017_0473_1 crossref_primary_10_1186_s12885_018_4644_7 crossref_primary_10_1007_s12282_021_01245_w crossref_primary_10_1038_s41523_024_00655_1 crossref_primary_10_1007_s00595_013_0762_7 crossref_primary_10_3390_jpm11121369 crossref_primary_10_1111_jan_14253 crossref_primary_10_3390_biom13081207 crossref_primary_10_1007_s11096_013_9833_5 crossref_primary_10_1186_s12885_019_5806_y crossref_primary_10_2147_PPA_S416843 crossref_primary_10_1016_j_jgo_2023_101599 crossref_primary_10_1111_ecc_12672 crossref_primary_10_1007_s00520_022_07326_6 crossref_primary_10_1093_jnci_djad109 crossref_primary_10_1097_MD_0000000000036704 crossref_primary_10_1186_2193_1801_3_282 crossref_primary_10_1016_j_jval_2013_11_011 crossref_primary_10_1136_bmjopen_2014_005285 crossref_primary_10_1007_s10549_014_3140_2 crossref_primary_10_1016_j_ejon_2022_102259 crossref_primary_10_1093_abm_kaab118 crossref_primary_10_1186_s13058_017_0911_9 crossref_primary_10_1080_0284186X_2020_1843190 crossref_primary_10_1055_s_0044_1785219 crossref_primary_10_1080_10410236_2017_1339370 crossref_primary_10_1016_j_clbc_2014_10_005 crossref_primary_10_1016_j_clbc_2024_07_009 crossref_primary_10_1158_1940_6207_CAPR_13_0389 crossref_primary_10_1056_NEJMoa2415566 crossref_primary_10_3390_cancers12123725 crossref_primary_10_1038_bjc_2016_276 crossref_primary_10_1016_j_bulcan_2018_08_005 crossref_primary_10_1016_j_breast_2025_103880 crossref_primary_10_1002_cam4_4140 crossref_primary_10_1200_JCO_2013_54_2258 crossref_primary_10_1200_JCO_2014_56_4583 crossref_primary_10_1016_j_ctrv_2015_01_002 crossref_primary_10_1007_s12282_014_0540_4 crossref_primary_10_1007_s10549_020_05748_6 crossref_primary_10_1016_j_ejso_2019_10_019 crossref_primary_10_1001_jamanetworkopen_2023_23752 crossref_primary_10_1158_1940_6207_CAPR_15_0322 crossref_primary_10_1177_20552076241288821 crossref_primary_10_1002_cncr_33596 crossref_primary_10_1016_j_annonc_2022_02_222 crossref_primary_10_1002_cncr_33595 crossref_primary_10_1007_s00520_015_2685_x crossref_primary_10_1007_s00520_022_07435_2 crossref_primary_10_1186_2193_1801_2_356 crossref_primary_10_1371_journal_pone_0262934 crossref_primary_10_1007_s00129_024_05296_w crossref_primary_10_3892_etm_2015_2437 crossref_primary_10_1007_s10549_017_4353_y crossref_primary_10_1007_s10549_013_2424_2 crossref_primary_10_1186_s13058_022_01576_2 crossref_primary_10_1684_bdc_2013_1830 crossref_primary_10_1186_s12913_022_08243_4 crossref_primary_10_18282_po3599 crossref_primary_10_1186_s13058_014_0427_5 crossref_primary_10_1007_s10549_019_05266_0 crossref_primary_10_1158_1940_6207_CAPR_17_0029 crossref_primary_10_1002_pon_4771 crossref_primary_10_1186_1471_2407_13_407 crossref_primary_10_1002_oby_21729 crossref_primary_10_1007_s00520_019_04671_x crossref_primary_10_1158_1078_0432_CCR_20_3974 crossref_primary_10_1159_000509651 crossref_primary_10_1177_11782234221145440 crossref_primary_10_1188_14_ONF_67_76 crossref_primary_10_1007_s10552_017_0851_9 crossref_primary_10_1007_s10549_018_5012_7 crossref_primary_10_2196_34995 crossref_primary_10_3390_cancers13010107 crossref_primary_10_7475_kjan_2020_32_3_223 crossref_primary_10_1016_j_breast_2023_05_007 crossref_primary_10_1016_j_maturitas_2019_09_007 crossref_primary_10_1007_s10549_023_06871_w crossref_primary_10_1007_s10549_021_06204_9 crossref_primary_10_1002_hsr2_70934 crossref_primary_10_2147_PPA_S353793 crossref_primary_10_1093_jncics_pky072 crossref_primary_10_1038_s41523_023_00511_8 crossref_primary_10_1080_10410236_2020_1751383 crossref_primary_10_1245_s10434_013_2924_7 crossref_primary_10_1002_cncr_32192 crossref_primary_10_1186_s12916_023_03156_3 crossref_primary_10_1002_cam4_3017 crossref_primary_10_3389_fgene_2021_662734 crossref_primary_10_1109_MPRV_2020_2993993 crossref_primary_10_3389_fimmu_2025_1559480 crossref_primary_10_1007_s10549_020_05912_y crossref_primary_10_1016_j_hoc_2013_05_008 crossref_primary_10_1007_s10549_016_3871_3 crossref_primary_10_1016_j_bulcan_2024_05_004 crossref_primary_10_1371_journal_pone_0152312 crossref_primary_10_1111_nin_12101 crossref_primary_10_1007_s00520_019_05247_5 crossref_primary_10_1007_s10549_024_07513_5 crossref_primary_10_1016_j_ctrv_2018_05_001 crossref_primary_10_1007_s10549_018_05073_z crossref_primary_10_3390_pharmacy6020053 crossref_primary_10_1111_ecc_12820 crossref_primary_10_1007_s10549_023_07097_6 crossref_primary_10_1016_S0007_4551_20_30045_X crossref_primary_10_1016_j_critrevonc_2024_104548 crossref_primary_10_1177_17588359251368733 crossref_primary_10_1016_j_breast_2019_07_001 crossref_primary_10_1177_1534735420980811 crossref_primary_10_1016_S1470_2045_20_30666_5 crossref_primary_10_1007_s10549_016_3928_3 crossref_primary_10_1186_s13027_017_0124_y crossref_primary_10_1200_JCO_2018_78_2110 crossref_primary_10_1371_journal_pone_0087027 crossref_primary_10_1007_s10549_023_07218_1 crossref_primary_10_1093_oncolo_oyaf172 crossref_primary_10_1159_000439570 crossref_primary_10_1016_j_ctrv_2017_03_009 crossref_primary_10_1016_j_breast_2017_06_001 crossref_primary_10_1177_1178223417694520 crossref_primary_10_1007_s10549_020_05900_2 crossref_primary_10_1016_j_actpha_2025_01_012 crossref_primary_10_1186_s40359_023_01355_4 crossref_primary_10_1186_s12905_022_01722_0 crossref_primary_10_1007_s12094_019_02048_4 crossref_primary_10_7759_cureus_27212 crossref_primary_10_1007_s10549_013_2422_4 crossref_primary_10_1007_s10549_014_2961_3 crossref_primary_10_1007_s11764_018_0682_z crossref_primary_10_1007_s00520_016_3229_8 crossref_primary_10_1159_000360702 crossref_primary_10_2196_23884 crossref_primary_10_1177_17588359251326710 crossref_primary_10_1007_s11912_019_0795_1 crossref_primary_10_1097_MD_0000000000019083 crossref_primary_10_1200_JCO_2014_57_1547 crossref_primary_10_1590_S0034_8910_2014048004799 crossref_primary_10_1093_jamiaopen_ooae006 crossref_primary_10_4137_JEN_S11268 crossref_primary_10_1111_ecc_12601 crossref_primary_10_1177_0272989X16640488 crossref_primary_10_3390_ijerph22050734 crossref_primary_10_1007_s10549_015_3565_2 crossref_primary_10_1016_j_clon_2017_10_015 crossref_primary_10_1002_cam4_3443 crossref_primary_10_1007_s12529_020_09908_2 crossref_primary_10_3390_cells11101696 crossref_primary_10_1007_s10549_022_06643_y crossref_primary_10_1007_s10549_014_3234_x crossref_primary_10_1371_journal_pone_0171169 crossref_primary_10_1007_s00520_013_1727_5 crossref_primary_10_1007_s10549_022_06741_x crossref_primary_10_1007_s11764_015_0511_6 crossref_primary_10_1001_jamanetworkopen_2022_44849 crossref_primary_10_1016_j_ejca_2025_115665 crossref_primary_10_1093_aje_kww178 crossref_primary_10_1158_1078_0432_CCR_23_2137 crossref_primary_10_1007_s10549_022_06510_w crossref_primary_10_1007_s10549_013_2795_4 crossref_primary_10_1188_17_ONF_E101_E110 crossref_primary_10_1007_s10549_019_05430_6 crossref_primary_10_1177_1078155219835297 crossref_primary_10_3389_fonc_2022_844926 crossref_primary_10_1007_s10549_020_05892_z crossref_primary_10_1016_j_ejon_2014_10_005 crossref_primary_10_1016_j_breast_2024_103765 crossref_primary_10_1136_bmjsrh_2024_202662 crossref_primary_10_1188_20_CJON_E13_E20 crossref_primary_10_3389_fphar_2024_1345482 crossref_primary_10_1016_j_breast_2024_103768 crossref_primary_10_1038_s41598_024_51751_y crossref_primary_10_1016_j_ijrobp_2023_07_018 crossref_primary_10_1016_j_sapharm_2020_02_004 crossref_primary_10_1080_08870446_2017_1296151 crossref_primary_10_1016_j_jgo_2018_11_008 crossref_primary_10_1016_j_jgo_2019_07_024 crossref_primary_10_1016_j_phymed_2020_153365 crossref_primary_10_32872_cpe_v2i1_2695 crossref_primary_10_1001_jamanetworkopen_2024_62365 crossref_primary_10_1186_s12905_023_02246_x crossref_primary_10_1093_jnci_djv245 crossref_primary_10_1016_j_breast_2022_04_010 crossref_primary_10_1016_S0140_6736_25_01013_X crossref_primary_10_1007_s11764_021_01046_2 crossref_primary_10_1093_abm_kaad037 crossref_primary_10_1200_JCO_2015_63_8619 crossref_primary_10_1245_s10434_020_08485_8 crossref_primary_10_1002_cnr2_2160 crossref_primary_10_1007_s00520_023_08170_y crossref_primary_10_1007_s10549_018_4811_1 crossref_primary_10_1093_oncolo_oyae146 crossref_primary_10_1097_MD_0000000000001071 crossref_primary_10_1007_s11096_022_01450_3 crossref_primary_10_1007_s00066_025_02391_2 crossref_primary_10_1093_abm_kaaf003 crossref_primary_10_1007_s11764_014_0374_2 crossref_primary_10_1016_j_ijrobp_2014_03_016 crossref_primary_10_1097_COC_0000000000001181 crossref_primary_10_1080_07347332_2014_992084 crossref_primary_10_7759_cureus_24780 crossref_primary_10_1007_s40262_021_01077_z crossref_primary_10_1016_j_breast_2022_01_012 crossref_primary_10_1038_s41523_022_00414_0 crossref_primary_10_1007_s00432_013_1402_8 crossref_primary_10_1016_j_annonc_2020_03_284 crossref_primary_10_3390_ph14020115 crossref_primary_10_1245_s10434_017_6094_x crossref_primary_10_1249_TJX_0000000000000213 crossref_primary_10_1007_s00520_024_08463_w crossref_primary_10_1007_s12282_024_01622_1 crossref_primary_10_1186_s40814_025_01676_8 crossref_primary_10_1007_s11764_023_01513_y crossref_primary_10_1016_j_japh_2022_03_001 crossref_primary_10_1188_14_ONF_660_668 crossref_primary_10_1590_1809_2950_e23004624en crossref_primary_10_1093_jnci_djx041 crossref_primary_10_1007_s11912_018_0702_1 crossref_primary_10_1089_jayao_2015_0051 crossref_primary_10_1371_journal_pone_0081677 crossref_primary_10_1200_JCO_24_01131 crossref_primary_10_1188_17_ONF_476_487 crossref_primary_10_1634_theoncologist_2015_0007 crossref_primary_10_1016_S1470_2045_15_70063_X crossref_primary_10_1111_jsm_12684 crossref_primary_10_1016_j_cct_2018_11_010 crossref_primary_10_1016_j_suronc_2017_07_006 crossref_primary_10_1007_s00520_024_08603_2 crossref_primary_10_1093_tbm_ibx061 crossref_primary_10_1016_j_ctrv_2021_102264 crossref_primary_10_1038_bjc_2013_464 crossref_primary_10_1007_s10549_019_05410_w crossref_primary_10_1007_s10549_020_05761_9 crossref_primary_10_1002_cam4_6937 crossref_primary_10_1177_1073274819883287 crossref_primary_10_1016_j_clbc_2024_12_011 crossref_primary_10_2147_PPA_S296747 crossref_primary_10_1007_s12094_022_02823_w crossref_primary_10_1007_s00520_024_08343_3 crossref_primary_10_1634_theoncologist_2015_0349 crossref_primary_10_1016_j_jval_2016_05_015 crossref_primary_10_1016_j_bulcan_2023_03_018 crossref_primary_10_1002_cncr_30318 crossref_primary_10_1016_j_breast_2015_08_008 crossref_primary_10_1007_s10549_020_05939_1 crossref_primary_10_2196_38073 crossref_primary_10_1016_j_jpba_2015_06_018 crossref_primary_10_1016_j_pec_2015_05_013 crossref_primary_10_1016_j_apjon_2025_100701 crossref_primary_10_1007_s10552_024_01900_5 crossref_primary_10_1007_s11121_024_01711_9 crossref_primary_10_7759_cureus_47869 crossref_primary_10_1007_s10549_017_4177_9 crossref_primary_10_1080_07399332_2020_1802460 crossref_primary_10_1007_s00520_019_04814_0 crossref_primary_10_1200_GO_24_00351 crossref_primary_10_1016_j_jpainsymman_2019_10_002 crossref_primary_10_1007_s00520_020_05585_9 crossref_primary_10_1186_s12913_019_4588_x crossref_primary_10_1200_JCO_24_02263 crossref_primary_10_1007_s10549_022_06849_0 crossref_primary_10_1371_journal_pone_0210972 crossref_primary_10_3389_fonc_2023_1222947 crossref_primary_10_1016_j_semradonc_2022_01_006 crossref_primary_10_1016_j_clbc_2022_08_009 crossref_primary_10_1111_tbj_14228 crossref_primary_10_1002_pds_4012 crossref_primary_10_1371_journal_pone_0210967 crossref_primary_10_3390_ijerph192315486 crossref_primary_10_1016_j_ctro_2020_02_003 crossref_primary_10_1097_GME_0000000000002504 crossref_primary_10_1177_03008916221096183 crossref_primary_10_3390_cancers15010316 crossref_primary_10_1007_s10549_018_4866_z crossref_primary_10_1093_annonc_mdt513 crossref_primary_10_3389_fonc_2023_1249160 crossref_primary_10_1200_JCO_18_00655 crossref_primary_10_1007_s11764_021_01114_7 crossref_primary_10_3390_cancers17172726 crossref_primary_10_1002_cncr_32946 crossref_primary_10_1177_2053369118824920 crossref_primary_10_1001_jamanetworkopen_2024_17873 crossref_primary_10_1186_s12885_023_11104_w crossref_primary_10_1016_j_ejon_2019_101706 crossref_primary_10_2147_PPA_S285768 crossref_primary_10_1007_s00404_018_5030_z crossref_primary_10_1007_s10549_022_06705_1 crossref_primary_10_1055_s_0036_1597974 crossref_primary_10_1002_pon_4362 crossref_primary_10_1007_s10552_017_0996_6 crossref_primary_10_1007_s11764_024_01599_y crossref_primary_10_1016_j_canep_2019_04_012 crossref_primary_10_1007_s10549_013_2585_z crossref_primary_10_1186_s12885_022_10362_4 crossref_primary_10_1016_j_ctrv_2024_102804 crossref_primary_10_3233_BD_230024 crossref_primary_10_1007_s10549_020_06071_w crossref_primary_10_1097_NCC_0000000000000522 crossref_primary_10_1016_j_amjsurg_2018_07_022 crossref_primary_10_1016_j_breast_2021_05_013 crossref_primary_10_1188_16_ONF_E143_E152 crossref_primary_10_1111_tbj_12783 crossref_primary_10_1007_s00520_020_05722_4 crossref_primary_10_1016_j_pec_2013_12_019 crossref_primary_10_1007_s10549_017_4615_8 crossref_primary_10_1093_abm_kay094 crossref_primary_10_1007_s10549_020_05579_5 crossref_primary_10_1007_s00737_024_01471_z crossref_primary_10_1016_j_bulcan_2021_04_016 crossref_primary_10_1016_j_nurpra_2021_11_007 crossref_primary_10_3389_fonc_2022_783487 crossref_primary_10_1007_s10549_017_4472_5 crossref_primary_10_1093_jamia_ocy118 crossref_primary_10_1016_j_coemr_2021_03_007 crossref_primary_10_1002_jso_27627 crossref_primary_10_1159_000547028 crossref_primary_10_1016_j_breast_2021_05_008 crossref_primary_10_1016_j_breast_2021_05_005 crossref_primary_10_1016_j_clbc_2016_03_006 crossref_primary_10_1007_s10549_022_06704_2 crossref_primary_10_1245_s10434_013_3170_8 crossref_primary_10_2217_cer_13_50 crossref_primary_10_1186_s12885_018_4660_7 crossref_primary_10_1002_cam4_2843 crossref_primary_10_1002_cncr_28490 crossref_primary_10_1097_COC_0000000000000351 crossref_primary_10_1177_1758835918766189 crossref_primary_10_2196_17742 crossref_primary_10_32635_2176_9745_RBC_2022v68n2_1960 crossref_primary_10_1136_bmjopen_2022_069971 crossref_primary_10_31362_patd_1621040 crossref_primary_10_1634_theoncologist_2015_0405 crossref_primary_10_1016_j_jpsychores_2020_110294 crossref_primary_10_1007_s10549_025_07701_x crossref_primary_10_1073_pnas_2408049121 crossref_primary_10_1016_j_ijrobp_2019_07_052 crossref_primary_10_1097_GME_0000000000001337 crossref_primary_10_1007_s10549_022_06583_7 crossref_primary_10_1007_s40261_023_01247_w crossref_primary_10_1007_s40262_017_0571_z crossref_primary_10_1093_annonc_mdy448 crossref_primary_10_1016_j_clbc_2016_12_002 crossref_primary_10_1007_s10549_017_4637_2 crossref_primary_10_1200_GO_21_00289 crossref_primary_10_1016_j_eclinm_2025_103493 crossref_primary_10_3390_cancers14164027 crossref_primary_10_1016_j_clon_2024_02_001 crossref_primary_10_2217_bmt_13_67 crossref_primary_10_1038_s41523_025_00762_7 crossref_primary_10_7453_gahmj_2013_046 crossref_primary_10_1002_pds_3631 crossref_primary_10_1177_10781552251323205 crossref_primary_10_1188_13_CJON_174_179 crossref_primary_10_1200_EDBK_25_473472 crossref_primary_10_1016_j_cct_2024_107712 crossref_primary_10_1007_s10549_018_4890_z crossref_primary_10_2217_bmt_14_48 crossref_primary_10_3390_ijerph14040394 crossref_primary_10_1016_j_breast_2025_104476 crossref_primary_10_1089_jwh_2016_6099 crossref_primary_10_1007_s10549_023_06887_2 crossref_primary_10_1002_pds_4751 crossref_primary_10_1016_j_breast_2015_06_010 crossref_primary_10_1016_j_breast_2020_06_012 crossref_primary_10_3390_cancers16234084 crossref_primary_10_1016_j_clbc_2017_12_003 crossref_primary_10_1007_s10549_025_07726_2 crossref_primary_10_1016_j_clbc_2017_12_002 crossref_primary_10_1007_s00520_023_07658_x crossref_primary_10_1007_s10549_022_06835_6 crossref_primary_10_1080_0284186X_2019_1643915 crossref_primary_10_1007_s10549_023_06989_x crossref_primary_10_1007_s11764_017_0674_4 crossref_primary_10_1007_s10880_020_09750_4 crossref_primary_10_1007_s12609_017_0248_5 crossref_primary_10_1093_jnci_djae280 crossref_primary_10_1007_s00432_014_1779_z crossref_primary_10_1007_s40265_024_02010_x crossref_primary_10_1093_annonc_mdz126 crossref_primary_10_1200_GO_24_00196 crossref_primary_10_1093_jnci_djy176 crossref_primary_10_1007_s00520_015_2950_z crossref_primary_10_1186_s12885_024_11910_w crossref_primary_10_1007_s10549_017_4317_2 crossref_primary_10_1186_s40814_022_00985_6 crossref_primary_10_1007_s10549_020_05549_x crossref_primary_10_1097_COC_0000000000000314 crossref_primary_10_1001_jamanetworkopen_2024_47541 crossref_primary_10_1002_phar_1399 crossref_primary_10_1007_s00404_020_05771_4 crossref_primary_10_3390_jpm13050754 crossref_primary_10_1002_cncr_33527 crossref_primary_10_1016_j_breast_2015_07_036 crossref_primary_10_2105_AJPH_2014_302490 crossref_primary_10_1007_s10549_022_06810_1 crossref_primary_10_1002_cncr_32434 crossref_primary_10_1080_13543784_2021_1983542 crossref_primary_10_1002_pon_5289 crossref_primary_10_1155_2024_7623194 crossref_primary_10_1177_1078155219831377 crossref_primary_10_1002_cncr_32433 crossref_primary_10_1590_1809_2950_e23004624pt crossref_primary_10_2196_27349 crossref_primary_10_2478_acph_2023_0043 crossref_primary_10_1007_s10549_021_06485_0 crossref_primary_10_1200_GO_24_00180 crossref_primary_10_1245_s10434_025_17861_1 crossref_primary_10_1007_s10549_020_06026_1 crossref_primary_10_1007_s10549_013_2417_1 crossref_primary_10_1007_s00520_023_07742_2 crossref_primary_10_1080_10408363_2019_1575643 crossref_primary_10_1186_s12885_023_11122_8 crossref_primary_10_1093_jnci_djae061 crossref_primary_10_1016_j_jgo_2021_05_011 crossref_primary_10_1007_s10549_017_4284_7 crossref_primary_10_1371_journal_pone_0187165 crossref_primary_10_2196_27576 crossref_primary_10_1038_s41523_023_00570_x |
| Cites_doi | 10.1093/annonc/mdr330 10.1016/j.breast.2007.11.001 10.1038/sj.bjc.6604525 10.1007/s10549-012-1961-4 10.1016/j.amjsurg.2006.06.018 10.1200/JCO.2006.10.1022 10.1007/s11606-011-1808-4 10.1038/bjc.2011.140 10.1200/JCO.2011.36.8399 10.1007/s10549-011-1578-z 10.1007/s10549-006-9193-0 10.1200/JCO.2007.11.5451 10.1002/pon.909 10.1007/s10549-010-1132-4 10.1002/pon.1593 10.1200/JOP.000082 10.1200/JCO.2004.11.064 10.1002/pon.1414 10.1093/jnci/djh060 10.1200/JCO.2009.25.9655 10.1007/s10549-007-9548-1 10.1188/07.ONF.1007-1016 10.1111/j.1365-2354.2011.01295.x 10.1159/000329006 10.1016/S1470-2045(05)70316-8 10.1093/jnci/88.21.1529 10.1093/annonc/mdn646 10.1007/s10549-011-1668-y 10.1007/s10549-009-0724-3 10.1038/sj.bjc.6604758 10.5600/mmrr.001.04.a04 10.3816/CBC.2007.n.038 10.1007/s10549-010-1139-x 10.1016/S1470-2045(07)70385-6 10.1056/NEJMoa040331 10.1586/erp.11.80 10.1097/01.mlr.0000257193.10760.7f 10.1023/A:1010684903199 10.3322/caac.20004 10.1200/JCO.2011.38.0261 10.1200/JCO.2003.07.071 10.1007/s10549-007-9774-6 10.1002/pon.891 10.1016/j.breast.2009.01.002 10.1200/JCO.2008.19.2419 10.1016/j.jclinepi.2009.06.005 10.1007/s10549-010-0952-6 10.1111/j.1524-4733.2006.00139.x 10.1016/S0140-6736(04)17666-6 10.1016/j.critrevonc.2009.02.001 10.1016/j.pec.2004.10.005 10.1056/NEJMoa032312 10.1007/s10549-011-1703-z 10.1188/08.CJON.213-221 10.1007/s10549-011-1762-1 10.1200/JCO.2010.33.3179 10.1016/j.amjsurg.2008.06.027 10.1001/archinte.166.14.1453 10.1200/JCO.2009.25.0894 10.1016/S0140-6736(97)11423-4 10.1016/S1470-2045(11)70364-3 10.1158/1940-6207.CAPR-11-0380 10.1093/jnci/92.13.1054 10.1097/GCO.0b013e328334e44e 10.1001/jama.295.17.2057 10.1634/theoncologist.2011-0037 10.1038/tpj.2009.14 10.1097/NCC.0b013e31824a7e18 10.1200/JCO.2001.19.2.322 10.1007/s10549-012-2066-9 10.1016/S0140-6736(11)60993-8 10.3109/13697137.2011.620658 10.3747/co.v18i0.899 10.1097/COC.0b013e3182436ec1 10.1159/000100444 10.1016/j.ejca.2012.03.004 |
| ContentType | Journal Article |
| Copyright | Springer Science+Business Media, LLC. 2012 2015 INIST-CNRS COPYRIGHT 2012 Springer |
| Copyright_xml | – notice: Springer Science+Business Media, LLC. 2012 – notice: 2015 INIST-CNRS – notice: COPYRIGHT 2012 Springer |
| DBID | AAYXX CITATION IQODW CGR CUY CVF ECM EIF NPM 3V. 7TO 7X7 7XB 88E 8AO 8C1 8FI 8FJ 8FK 8G5 ABUWG AFKRA AZQEC BENPR CCPQU DWQXO FYUFA GHDGH GNUQQ GUQSH H94 K9- K9. M0R M0S M1P M2O MBDVC PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS Q9U 7X8 5PM |
| DOI | 10.1007/s10549-012-2114-5 |
| DatabaseName | CrossRef Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Oncogenes and Growth Factors Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) ProQuest Pharma Collection Public Health Database Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) Research Library (Alumni) ProQuest Central ProQuest Central UK/Ireland ProQuest Central Essentials ProQuest Central ProQuest One ProQuest Central Korea Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student ProQuest Research Library AIDS and Cancer Research Abstracts Consumer Health Database ProQuest Health & Medical Complete (Alumni) Consumer Health Database ProQuest Health & Medical Collection Medical Database ProQuest Research Library Research Library (Corporate) ProQuest Central Premium ProQuest One Academic (New) ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic (retired) ProQuest One Academic UKI Edition ProQuest Central China ProQuest Central Basic MEDLINE - Academic PubMed Central (Full Participant titles) |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Research Library Prep ProQuest Central Student Oncogenes and Growth Factors Abstracts ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing Research Library (Alumni Edition) ProQuest Pharma Collection ProQuest Family Health (Alumni Edition) ProQuest Central China ProQuest Central ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Health & Medical Research Collection AIDS and Cancer Research Abstracts ProQuest Research Library ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest Public Health ProQuest Central Basic ProQuest Family Health ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic Research Library Prep MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1573-7217 |
| EndPage | 478 |
| ExternalDocumentID | PMC3607286 2723818261 A356447246 22689091 26200810 10_1007_s10549_012_2114_5 |
| Genre | Research Support, Non-U.S. Gov't Systematic Review Journal Article Research Support, N.I.H., Extramural |
| GrantInformation_xml | – fundername: NCI NIH HHS grantid: R01 CA112223 – fundername: NCI NIH HHS grantid: K07 CA140159 – fundername: NCI NIH HHS grantid: R01CA112223 – fundername: NCI NIH HHS grantid: R25 CA057712 – fundername: NCI NIH HHS grantid: K07CA140159 – fundername: National Cancer Institute : NCI grantid: K07 CA140159 || CA |
| GroupedDBID | --- -53 -5E -5G -BR -EM -XW -Y2 -~C .86 .GJ .VR 06C 06D 0R~ 0VY 199 1N0 1SB 2.D 203 23N 28- 29~ 2J2 2JN 2JY 2KG 2KM 2LR 2P1 2VQ 2~H 30V 3O- 3V. 4.4 406 408 409 40D 40E 53G 5GY 5QI 5VS 67Z 6NX 78A 7X7 88E 8AO 8C1 8FI 8FJ 8G5 8TC 8UJ 95- 95. 95~ 96X AAAVM AABHQ AACDK AAHNG AAIAL AAJBT AAJKR AANXM AANZL AARHV AARTL AASML AATNV AATVU AAUYE AAWCG AAYIU AAYQN AAYTO AAYZH ABAKF ABBBX ABBXA ABDZT ABECU ABFTV ABHLI ABHQN ABIPD ABJNI ABJOX ABKCH ABKTR ABLJU ABMNI ABMQK ABNWP ABPLI ABQBU ABQSL ABSXP ABTEG ABTKH ABTMW ABULA ABUWG ABWNU ABXPI ACAOD ACBXY ACDTI ACGFS ACHSB ACHVE ACHXU ACIHN ACKNC ACMDZ ACMLO ACOKC ACOMO ACPIV ACPRK ACUDM ACZOJ ADBBV ADHHG ADHIR ADIMF ADINQ ADJJI ADKNI ADKPE ADRFC ADTPH ADURQ ADYFF ADZKW AEAQA AEBTG AEFIE AEFQL AEGAL AEGNC AEJHL AEJRE AEKMD AEMSY AENEX AEOHA AEPYU AESKC AETLH AEVLU AEXYK AFBBN AFDYV AFEXP AFFNX AFJLC AFKRA AFLOW AFQWF AFWTZ AFZKB AGAYW AGDGC AGGDS AGJBK AGMZJ AGQEE AGQMX AGRTI AGVAE AGWIL AGWZB AGYKE AHAVH AHBYD AHIZS AHKAY AHMBA AHSBF AHYZX AIAKS AIGIU AIIXL AILAN AITGF AJBLW AJRNO AJZVZ AKMHD ALIPV ALMA_UNASSIGNED_HOLDINGS ALWAN AMKLP AMXSW AMYLF AMYQR AOCGG ARMRJ ASPBG AVWKF AXYYD AZFZN AZQEC B-. BA0 BBWZM BDATZ BENPR BGNMA BKNYI BPHCQ BSONS BVXVI CAG CCPQU COF CS3 CSCUP DDRTE DL5 DNIVK DPUIP DU5 DWQXO EBD EBLON EBS EIOEI EJD EMB EMOBN EN4 ESBYG F5P FEDTE FERAY FFXSO FIGPU FINBP FNLPD FRRFC FSGXE FWDCC FYUFA G-Y G-Z GGCAI GGRSB GJIRD GNUQQ GNWQR GQ6 GQ7 GQ8 GRRUI GUQSH GXS H13 HF~ HG5 HG6 HMCUK HMJXF HQYDN HRMNR HVGLF HZ~ I09 IAO ICW IHE IHR IHW IJ- IKXTQ IMOTQ INH INR ITC ITM IWAJR IXC IZIGR IZQ I~X I~Z J-C J0Z JBSCW JCJTX JZLTJ K9- KDC KOV KOW KPH LAK LLZTM M0R M1P M2O M4Y MA- N2Q N9A NB0 NDZJH NPVJJ NQJWS NU0 O9- O93 O9G O9I O9J OAM OVD P19 P2P P9S PF0 PQQKQ PROAC PSQYO PT4 PT5 Q2X QOK QOR QOS R4E R89 R9I RHV RNI ROL RPX RRX RSV RZC RZE RZK S16 S1Z S26 S27 S28 S37 S3B SAP SCLPG SDE SDH SDM SHX SISQX SJYHP SMD SNE SNPRN SNX SOHCF SOJ SPISZ SRMVM SSLCW SSXJD STPWE SV3 SZ9 SZN T13 T16 TEORI TSG TSK TSV TT1 TUC U2A U9L UDS UG4 UKHRP UOJIU UTJUX UZXMN VC2 VFIZW W23 W48 WJK WK8 YLTOR Z45 Z7U Z7W Z81 Z82 Z83 Z87 Z8O Z8Q Z8U Z8V Z8W Z91 ZGI ZMTXR ZOVNA ZXP ~EX ~KM AAPKM AAYXX ABBRH ABDBE ABFSG ABRTQ ACSTC ADHKG AEZWR AFDZB AFFHD AFHIU AFOHR AGQPQ AHPBZ AHWEU AIXLP ATHPR AYFIA CITATION PHGZM PHGZT PJZUB PPXIY IQODW CGR CUY CVF ECM EIF NPM 7TO 7XB 8FK H94 K9. MBDVC PKEHL PQEST PQUKI PRINS Q9U 7X8 PUEGO 5PM |
| ID | FETCH-LOGICAL-c664t-e9e1549c7f191cb71b2197e4e05f7fa1f1e0030063f74379c919589921a2f6d03 |
| IEDL.DBID | RSV |
| ISICitedReferencesCount | 565 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000306730500002&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 0167-6806 1573-7217 |
| IngestDate | Tue Nov 04 01:36:48 EST 2025 Thu Oct 02 07:17:17 EDT 2025 Sat Nov 08 16:51:26 EST 2025 Sat Nov 29 13:06:30 EST 2025 Sun Nov 23 08:51:02 EST 2025 Thu May 22 21:23:25 EDT 2025 Mon Jul 21 05:31:48 EDT 2025 Mon Jul 21 09:14:39 EDT 2025 Sat Nov 29 05:41:15 EST 2025 Tue Nov 18 22:53:27 EST 2025 Fri Feb 21 02:33:54 EST 2025 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 2 |
| Keywords | Adherence Systematic review Adjuvant hormonal therapy Survivorship Human Breast disease Hormone therapy Survivor Adjuvant treatment Breast cancer Malignant tumor Review Adhesion Mammary gland diseases Cancer |
| Language | English |
| License | http://www.springer.com/tdm CC BY 4.0 |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c664t-e9e1549c7f191cb71b2197e4e05f7fa1f1e0030063f74379c919589921a2f6d03 |
| Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 14 ObjectType-Article-1 ObjectType-Feature-2 ObjectType-Review-3 content type line 23 ObjectType-Undefined-4 |
| OpenAccessLink | https://www.ncbi.nlm.nih.gov/pmc/articles/3607286 |
| PMID | 22689091 |
| PQID | 1030117915 |
| PQPubID | 36266 |
| PageCount | 20 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_3607286 proquest_miscellaneous_1027678615 proquest_journals_1030117915 gale_infotracmisc_A356447246 gale_infotracacademiconefile_A356447246 gale_healthsolutions_A356447246 pubmed_primary_22689091 pascalfrancis_primary_26200810 crossref_primary_10_1007_s10549_012_2114_5 crossref_citationtrail_10_1007_s10549_012_2114_5 springer_journals_10_1007_s10549_012_2114_5 |
| PublicationCentury | 2000 |
| PublicationDate | 2012-07-01 |
| PublicationDateYYYYMMDD | 2012-07-01 |
| PublicationDate_xml | – month: 07 year: 2012 text: 2012-07-01 day: 01 |
| PublicationDecade | 2010 |
| PublicationPlace | Boston |
| PublicationPlace_xml | – name: Boston – name: Dordrecht – name: Netherlands |
| PublicationTitle | Breast cancer research and treatment |
| PublicationTitleAbbrev | Breast Cancer Res Treat |
| PublicationTitleAlternate | Breast Cancer Res Treat |
| PublicationYear | 2012 |
| Publisher | Springer US Springer Springer Nature B.V |
| Publisher_xml | – name: Springer US – name: Springer – name: Springer Nature B.V |
| References | (CR20) 1998; 351 Wengstrom (CR76) 2008; 17 Goss, Ingle, Martino, Robert, Muss, Piccart, Castiglione, Tu, Shepherd, Pritchard, Livingston, Davidson, Norton, Perez, Abrams, Therasse, Palmer, Pater (CR4) 2003; 349 Ganz, Greendale, Petersen, Zibecchi, Kahn, Belin (CR70) 2000; 92 Garreau, DeLaMelena, Walts, Karamlou, Johnson (CR55) 2006; 192 (CR3) 2008; 9 Mann, Smith, Hellier, Balabanovic, Hamed, Grunfeld, Hunter (CR74) 2012; 13 Riley, Warren, Harlan, Blackwell (CR31) 2011; 1 (CR2) 2005; 365 Banning (CR18) 2012; 21 (CR6) 2011; 378 Partridge, Wang, Winer, Avorn (CR23) 2003; 21 van Herk-Sukel, van del Poll-Franse, Voogd, Nieuwenhuijzen, Coebergh, Herings (CR40) 2010; 122 Presant, Bosserman, Young, Vakil, Horns, Upadhyaya, Ebrahimi, Yeon, Howard (CR60) 2007; 7 Kelly, Agius (CR78) 2006; 20 Hunter, Conventry, Hamed, Fentiman, Grunfeld (CR71) 2009; 18 Ziller, Kalder, Albert, Hozhauer, Ziller, Wagner, Hadji (CR27) 2009; 20 Demissie, Silliman, Lash (CR33) 2001; 19 Hershman, Shao, Kushi, Buono, Tsai, Fehrenbacher, Kwan, Gomez, Neugut (CR11) 2011; 126 CR7 CR49 Guth, Huang, Schotzau, Zanetti-Dallenback, Holzgreve, Bitzer, Wight (CR26) 2008; 99 CR48 CR47 Wu, Lund, Kimmick, Richardson, Sabatino, Chen, Fleming, Morris, Huang, Trentham-Dietz, Lipscomb (CR80) 2012; 30 Lash, Fox, Westrup, Fink, Silliman (CR35) 2006; 99 Potosky, Han, Rowland, Klabunde, Smith, Aziz, Earle, Ayanian, Ganz, Stefanek (CR51) 2011; 26 Mortimer (CR75) 2010; 22 Miaskowski, Shockney, Chlebowski (CR77) 2008; 12 CR82 Pellegrini, Sarradon-Eck, Soussan, Lacour, Largillier, Tallet, Tarpin, Julian-Reynier (CR61) 2010; 19 Mishel, Germino, Gil, Belyea, Laney, Stewart, Porter, Clayton (CR73) 2005; 14 Nelson, Vesco, Haney, Fu, Nedrow, Miller, Nicolaidis, Walker, Humphrey (CR66) 2006; 295 Sedjo, Devine (CR28) 2011; 125 Neugut, Subar, Wilde, Stratton, Brouse, Hillyer, Grann, Hershman (CR44) 2011; 29 McCowan, Shearer, Donnan, Dewar, Crilly, Thompson, Fahey (CR9) 2008; 99 Ruddy, Mayer, Partridge (CR21) 2009; 59 Ganz, Kwan, Stanton, Krupnick, Rowland, Meyerowitz, Bower, Belin (CR69) 2004; 96 Henry, Giles, Ang, Mohan, Dadabhoy, Robarge, Hayden, Lemler, Shahverdi, Powers, Li, Flockhart, Stearns, Hayes, Storniolo, Clauw (CR59) 2008; 111 Cimprich, Janz, Northouse, Wren, Given, Given (CR68) 2005; 14 Livaudais, Hershman, Habel, Kushi, Gomez, Li, Neugut, Fehrenbacher, Thompson, Coronado (CR81) 2012; 131 Ma, Barone, Wallis, Wu, Garcia, Estabrook, Rosenbaum-Smith, Tartter (CR25) 2008; 196 Dogrell (CR15) 2011; 129 Wigertz, Ahlgren, Holmqvist, Fornander, Adolfsson, Lindman, Bergkvist, Lambe (CR32) 2012; 133 Henry, Azzouz, Desta, Li, Nguyen, Lemler, Hayden, Tarpinian, Yakim, Flockhart, Stearns, Hayes, Storniolo (CR62) 2012; 30 Gotay, Dunn (CR16) 2011; 11 CR53 Hadji (CR14) 2010; 73 Dittmer, Roeder, Hoellen, Salehin, Thill, Fischer (CR30) 2011; 32 van de Water, Bastiaannet, Hille, Kranenbarg, Putter, Seynaeve, Paridaens, de Craen, Westendorp, Liefers, van de Velde (CR12) 2012; 17 CR50 Guth, Myrick, Schotzau, Kilic, Schmid (CR41) 2011; 129 Verma, Madarnas, Sehdev, Martin, Bajcar (CR17) 2011; 18 Kahn, Schneider, Malin, Adams, Epstein (CR36) 2007; 45 Huiart, Dell’Aniello, Suissa (CR45) 2011; 104 Chlebowski, Geller (CR13) 2006; 71 Fisher, Dignam, Bryant, DeCillis, Wickerham, Wolmark, Costantino, Redmond, Fisher, Bowman, Deschenes, Dimitrov, Margolese, Robidoux, Shibata, Terz, Paterson, Feldman, Farrar, Evans, Lickley (CR1) 1996; 88 Nedrow, Miller, Walker, Nygren, Huffman, Nelson (CR65) 2006; 166 Rae, Sikora, Henry, Li, Kim, Oesterreich, Skaar, Nguyen, Desta, Storniolo, Flockhart, Hayes, Stearns (CR39) 2009; 9 Fellowes, Fallowfield, Saunder, Haughton (CR57) 2001; 66 Hickey, Saunders, Stuckey (CR67) 2005; 6 Dezentje, van Blijderveen, Gelderblom, Putter, van Herk-Sukel, Casparie, Egberts, Nortier, Guchelaar (CR10) 2010; 28 Cluze, Rey, Huiart, BenDiane, Bouhnik, Berenger, Carrieri, Giorgi (CR54) 2012; 23 Salgado, Zivian (CR58) 2006; 100 Moher, Liberati, Tetzlaff, Altman (CR19) 2009; 62 Peterson, Nau, Cramer, Benner, Gwadry-Sridhar, Nichol (CR22) 2007; 10 Hershman, Kushi, Shao, Buono, Kershenbaum, Tsai, Fehrenbacher, Gomez, Miles, Neugut (CR83) 2010; 28 Cella, Fallowfield (CR56) 2008; 107 Schwartzberg, Cobb, Senecal, Henry, Kulig, Walker, Houts, Stepanski (CR38) 2009; 18 CR64 Burstein, Griggs, Prestrud, Temin (CR8) 2010; 6 Thompson, Johnson, Quinlan, Hillman, Fontecha, Bray, Purdie, Jordan, Ferraldeschi, Latif, Hadfield, Clarke, Ashcroft, Evans, Howell, Nikoloff, Lawrence, Newman (CR29) 2011; 125 CR63 Kimmick, Anderson, Camacho, Bhosle, Hwang, Balkrishman (CR43) 2009; 27 Meneses, McNees, Loerzel, Su, Zhang, Hassey (CR72) 2007; 34 Owusu, Buist, Field, Lash, Thwin, Geiger, Quinn, Frost, Prout, Yood, Wei, Silliman (CR37) 2008; 26 Albert, Zemlin, Hadji, Ziller, Kuhler, Frank-Hahn, Wagner, Kalder (CR79) 2011; 6 Fink, Gurwitz, Rakowski, Guadagnoli, Silliman (CR34) 2004; 22 Coombes, Hall, Gibson, Paridaens, Jassem, Delozier, Jones, Alvarez, Bertelli, Ortmann, Coates, Bajetta, Dodwell, Coleman, Fallowfield, Mickiewicz, Andersen, Lonning, Cocconi, Stewart, Stuart, Snowdon, Carpentieri, Massimini, Bliss (CR5) 2004; 350 Grunfeld, Hunter, Sikka, Mittal (CR24) 2005; 59 Partridge, LaFountain, Mayer, Taylor, Winer, Asnis-Alibozek (CR42) 2008; 26 Lin, Zhang, Manson (CR52) 2011; 4 Nekhlyudov, Lingling, Ross-Degnan, Wagner (CR46) 2011; 130 AH Partridge (2114_CR42) 2008; 26 Early Breast Cancer Trialists’ Collaborative Group (2114_CR6) 2011; 378 MS Hunter (2114_CR71) 2009; 18 KL Kahn (2114_CR36) 2007; 45 BA Salgado (2114_CR58) 2006; 100 RT Chlebowski (2114_CR13) 2006; 71 JC Livaudais (2114_CR81) 2012; 131 NL Henry (2114_CR62) 2012; 30 US Albert (2114_CR79) 2011; 6 S Demissie (2114_CR33) 2001; 19 RC Coombes (2114_CR5) 2004; 350 Early Breast Cancer Trialists’ Collaborative Group (2114_CR20) 1998; 351 AI Neugut (2114_CR44) 2011; 29 KD Meneses (2114_CR72) 2007; 34 PA Ganz (2114_CR69) 2004; 96 JM Rae (2114_CR39) 2009; 9 MH Mishel (2114_CR73) 2005; 14 The Arimidex, Tamoxifen, Alone or in Combination (ATAC) Trialists’ Group (2114_CR3) 2008; 9 AL Potosky (2114_CR51) 2011; 26 2114_CR49 K Ruddy (2114_CR21) 2009; 59 2114_CR48 2114_CR47 B Cimprich (2114_CR68) 2005; 14 HD Nelson (2114_CR66) 2006; 295 U Guth (2114_CR26) 2008; 99 The Arimidex, Tamoxifen, Alone or in Combination (ATAC) Trialists’ Group (2114_CR2) 2005; 365 PE Goss (2114_CR4) 2003; 349 W Water van de (2114_CR12) 2012; 17 2114_CR7 2114_CR82 Y Wengstrom (2114_CR76) 2008; 17 DL Hershman (2114_CR11) 2011; 126 GF Riley (2114_CR31) 2011; 1 JR Garreau (2114_CR55) 2006; 192 AH Partridge (2114_CR23) 2003; 21 C Owusu (2114_CR37) 2008; 26 D Fellowes (2114_CR57) 2001; 66 JE Mortimer (2114_CR75) 2010; 22 RL Sedjo (2114_CR28) 2011; 125 L Huiart (2114_CR45) 2011; 104 TL Lash (2114_CR35) 2006; 99 M Hickey (2114_CR67) 2005; 6 S Verma (2114_CR17) 2011; 18 X Wu (2114_CR80) 2012; 30 HJ Burstein (2114_CR8) 2010; 6 A Kelly (2114_CR78) 2006; 20 PA Ganz (2114_CR70) 2000; 92 DL Hershman (2114_CR83) 2010; 28 B Fisher (2114_CR1) 1996; 88 G Kimmick (2114_CR43) 2009; 27 C Dittmer (2114_CR30) 2011; 32 C McCowan (2114_CR9) 2008; 99 A Wigertz (2114_CR32) 2012; 133 2114_CR53 2114_CR50 L Nekhlyudov (2114_CR46) 2011; 130 P Hadji (2114_CR14) 2010; 73 JH Lin (2114_CR52) 2011; 4 LS Schwartzberg (2114_CR38) 2009; 18 SA Dogrell (2114_CR15) 2011; 129 M Banning (2114_CR18) 2012; 21 V Ziller (2114_CR27) 2009; 20 NL Henry (2114_CR59) 2008; 111 D Moher (2114_CR19) 2009; 62 AK Fink (2114_CR34) 2004; 22 C Gotay (2114_CR16) 2011; 11 AMT Ma (2114_CR25) 2008; 196 MPP Herk-Sukel van (2114_CR40) 2010; 122 E Mann (2114_CR74) 2012; 13 I Pellegrini (2114_CR61) 2010; 19 U Guth (2114_CR41) 2011; 129 D Cella (2114_CR56) 2008; 107 CA Presant (2114_CR60) 2007; 7 AM Peterson (2114_CR22) 2007; 10 EA Grunfeld (2114_CR24) 2005; 59 C Cluze (2114_CR54) 2012; 23 2114_CR64 2114_CR63 VO Dezentje (2114_CR10) 2010; 28 A Nedrow (2114_CR65) 2006; 166 C Miaskowski (2114_CR77) 2008; 12 AM Thompson (2114_CR29) 2011; 125 23400580 - Breast Cancer Res Treat. 2013 Feb;138(1):325-8. doi: 10.1007/s10549-013-2422-4. |
| References_xml | – volume: 23 start-page: 882 year: 2012 end-page: 890 ident: CR54 article-title: Adjuvant endocrine therapy with tamoxifen in young women with breast cancer: determinants of interruptions vary over time publication-title: Ann Oncol doi: 10.1093/annonc/mdr330 – volume: 17 start-page: 227 issue: 3 year: 2008 end-page: 238 ident: CR76 article-title: Effectively nursing patients receiving aromatase inhibitor therapy publication-title: Breast doi: 10.1016/j.breast.2007.11.001 – volume: 99 start-page: 428 year: 2008 end-page: 433 ident: CR26 article-title: Target and reality of adjuvant endocrine therapy in postmenopausal patients with invasive breast cancer publication-title: Br J Cancer doi: 10.1038/sj.bjc.6604525 – volume: 133 start-page: 367 year: 2012 end-page: 373 ident: CR32 article-title: Adherence and discontinuation of adjuvant hormonal therapy in breast cancer patients: a population-based study publication-title: Breast Cancer Res Treat doi: 10.1007/s10549-012-1961-4 – ident: CR49 – volume: 192 start-page: 496 year: 2006 end-page: 498 ident: CR55 article-title: Side effects of aromatase inhibitors versus tamoxifen: the patients’ perspective publication-title: Am J Surg doi: 10.1016/j.amjsurg.2006.06.018 – volume: 26 start-page: 549 issue: 4 year: 2008 end-page: 555 ident: CR37 article-title: Predictors of tamoxifen discontinuation among older women with estrogen receptor-positive breast cancer publication-title: J Clin Oncol doi: 10.1200/JCO.2006.10.1022 – volume: 26 start-page: 1403 issue: 12 year: 2011 end-page: 1410 ident: CR51 article-title: Difference between primary care physicians’ and oncologists’ knowledge, attitudes and practices regarding the care of cancer survivors publication-title: J Gen Intern Med doi: 10.1007/s11606-011-1808-4 – volume: 104 start-page: 1558 year: 2011 end-page: 1563 ident: CR45 article-title: Use of tamoxifen and aromatase inhibitors in a large population-based cohort of women with breast cancer publication-title: Br J Cancer doi: 10.1038/bjc.2011.140 – volume: 30 start-page: 142 issue: 2 year: 2012 end-page: 150 ident: CR80 article-title: Influence of race, insurance, socioeconomic status, and hospital type on receipt of guideline-concordant adjuvant systemic therapy for locoregional breast cancers publication-title: J Clin Oncol doi: 10.1200/JCO.2011.36.8399 – volume: 129 start-page: 299 year: 2011 end-page: 308 ident: CR15 article-title: Adherence to oral endocrine treatments in women with breast cancer: can it be improved? publication-title: Breast Cancer Res Treat doi: 10.1007/s10549-011-1578-z – volume: 99 start-page: 215 year: 2006 end-page: 220 ident: CR35 article-title: Adherence to tamoxifen over the five-year course publication-title: Breast Cancer Res Treat doi: 10.1007/s10549-006-9193-0 – volume: 26 start-page: 556 issue: 4 year: 2008 end-page: 562 ident: CR42 article-title: Adherence to initial adjuvant anastrozole therapy among women with early-stage breast cancer publication-title: J Clin Oncol doi: 10.1200/JCO.2007.11.5451 – volume: 18 start-page: S3 issue: Suppl 1 year: 2011 end-page: S9 ident: CR17 article-title: Patient adherence to aromatase inhibitor treatment in the adjuvant setting publication-title: Curr Oncol – volume: 14 start-page: 962 year: 2005 end-page: 972 ident: CR73 article-title: Benefits from an uncertainty management intervention for African-American and Caucasian older long-term breast cancer survivors publication-title: Psycho-Oncology doi: 10.1002/pon.909 – volume: 126 start-page: 529 year: 2011 end-page: 537 ident: CR11 article-title: Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer publication-title: Breast Cancer Res Treat doi: 10.1007/s10549-010-1132-4 – volume: 19 start-page: 472 year: 2010 end-page: 479 ident: CR61 article-title: Women’s perception and experience of adjuvant tamoxifen therapy account for their adherence: breast cancer patients’ point of view publication-title: Pyscho-Oncology doi: 10.1002/pon.1593 – volume: 6 start-page: 243 issue: 5 year: 2010 end-page: 246 ident: CR8 article-title: American Society of Clinical Oncology clinical practice guideline update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer publication-title: J Oncol Pract doi: 10.1200/JOP.000082 – volume: 22 start-page: 3309 issue: 16 year: 2004 end-page: 3315 ident: CR34 article-title: Patient beliefs and tamoxifen discontinuance in older women with estrogen receptor-positive breast cancer publication-title: J Clin Oncol doi: 10.1200/JCO.2004.11.064 – volume: 18 start-page: 560 year: 2009 end-page: 563 ident: CR71 article-title: Evaluation of a group cognitive behavioral intervention for women suffering from menopausal symptoms following breast cancer treatment publication-title: Psycho-Oncology doi: 10.1002/pon.1414 – volume: 378 start-page: 771 year: 2011 end-page: 784 ident: CR6 article-title: Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials publication-title: Lancet – volume: 96 start-page: 376 issue: 5 year: 2004 end-page: 387 ident: CR69 article-title: Quality of life at the end of primary treatment of breast cancer: first results from the moving beyond cancer randomized trial publication-title: J Natl Cancer Inst doi: 10.1093/jnci/djh060 – ident: CR50 – volume: 28 start-page: 4120 issue: 27 year: 2010 end-page: 4128 ident: CR83 article-title: Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8,769 early-stage breast cancer patients publication-title: J Clin Oncol doi: 10.1200/JCO.2009.25.9655 – volume: 107 start-page: 167 year: 2008 end-page: 180 ident: CR56 article-title: Recognition and management of treatment-related side effects for breast cancer patients receiving adjuvant endocrine therapy publication-title: Breast Cancer Res Treat doi: 10.1007/s10549-007-9548-1 – volume: 34 start-page: 1007 issue: 5 year: 2007 end-page: 1016 ident: CR72 article-title: Transition from treatment to survivorship: effects of a psychoeducational intervention on quality of life in breast cancer survivors publication-title: Oncol Nurs Forum doi: 10.1188/07.ONF.1007-1016 – volume: 21 start-page: 10 year: 2012 end-page: 19 ident: CR18 article-title: Adherence to adjuvant therapy in post-menopausal breast cancer patients: a review publication-title: Eur J Cancer Care doi: 10.1111/j.1365-2354.2011.01295.x – volume: 6 start-page: 221 issue: 3 year: 2011 end-page: 226 ident: CR79 article-title: The impact of breast care nurses on patients’ satisfaction, understanding of the disease, and adherence to adjuvant endocrine therapy publication-title: Breast Care doi: 10.1159/000329006 – volume: 6 start-page: 687 year: 2005 end-page: 695 ident: CR67 article-title: Management of menopausal symptoms in patients with breast cancer: an evidence-based approach publication-title: Lancet Oncol doi: 10.1016/S1470-2045(05)70316-8 – volume: 88 start-page: 1529 year: 1996 end-page: 1542 ident: CR1 article-title: Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors publication-title: J Natl Cancer Inst doi: 10.1093/jnci/88.21.1529 – volume: 20 start-page: 431 year: 2009 end-page: 436 ident: CR27 article-title: Adherence to adjuvant endocrine therapy in postmenopausal women with breast cancer publication-title: Ann Oncol doi: 10.1093/annonc/mdn646 – ident: CR64 – volume: 129 start-page: 799 year: 2011 end-page: 807 ident: CR41 article-title: Drug switch because of treatment-related adverse side effects in endocrine adjuvant breast cancer therapy: how often and how often does it work? publication-title: Breast Cancer Res Treat doi: 10.1007/s10549-011-1668-y – volume: 122 start-page: 843 year: 2010 end-page: 851 ident: CR40 article-title: Half of breast cancer patients discontinue tamoxifen and any endocrine treatment before the end of the recommended treatment period of 5 years: a population-based analysis publication-title: Breast Cancer Res Treat doi: 10.1007/s10549-009-0724-3 – volume: 99 start-page: 1763 year: 2008 end-page: 1768 ident: CR9 article-title: Cohort study examining tamoxifen adherence and its relationship to mortality in women with breast cancer publication-title: Br J Cancer doi: 10.1038/sj.bjc.6604758 – volume: 1 start-page: E1 issue: 4 year: 2011 end-page: E21 ident: CR31 article-title: Endocrine therapy use among elderly hormone receptor-positive breast cancer patients enrolled in Medicare Part D publication-title: Medicare Medicaid Res Rev doi: 10.5600/mmrr.001.04.a04 – ident: CR47 – volume: 7 start-page: 775 issue: 10 year: 2007 end-page: 778 ident: CR60 article-title: Aromatase inhibitor-associated arthralgia and/or bone pain: frequency and characterization in non-clinical trial patients publication-title: Clin Breast Cancer doi: 10.3816/CBC.2007.n.038 – volume: 125 start-page: 279 year: 2011 end-page: 287 ident: CR29 article-title: Comprehensive CYP256 genotype and adherence affect outcome in breast cancer patients treated with tamoxifen monotherapy publication-title: Breast Cancer Res Treat doi: 10.1007/s10549-010-1139-x – volume: 9 start-page: 45 year: 2008 end-page: 53 ident: CR3 article-title: Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial publication-title: Lancet Oncol doi: 10.1016/S1470-2045(07)70385-6 – volume: 350 start-page: 1081 year: 2004 end-page: 1092 ident: CR5 article-title: A randomized trial of exemestane after two or three years of tamoxifen therapy in postmenopausal women with primary breast cancer publication-title: N Engl J Med doi: 10.1056/NEJMoa040331 – volume: 11 start-page: 709 issue: 6 year: 2011 end-page: 715 ident: CR16 article-title: Adherence to long-term adjuvant hormonal therapy for breast cancer publication-title: Expert Rev Pharmacoeconomics Outcomes Res doi: 10.1586/erp.11.80 – ident: CR53 – volume: 45 start-page: 431 issue: 5 year: 2007 end-page: 439 ident: CR36 article-title: Patient centered experiences in breast cancer: predicting long-term adherence to tamoxifen use publication-title: Med Care doi: 10.1097/01.mlr.0000257193.10760.7f – volume: 66 start-page: 73 year: 2001 end-page: 81 ident: CR57 article-title: Tolerability of hormone therapies for breast cancer: how informative are documented symptom profiles in medical notes for ‘well-tolerated’ treatments? publication-title: Breast Cancer Res Treat doi: 10.1023/A:1010684903199 – volume: 59 start-page: 56 year: 2009 end-page: 66 ident: CR21 article-title: Patient adherence and persistence with oral anticancer treatment publication-title: CA Cancer J Clin doi: 10.3322/caac.20004 – volume: 30 start-page: 936 issue: 9 year: 2012 end-page: 942 ident: CR62 article-title: Predictors of aromatase inhibitor discontinuation as a result of treatment-emergent symptoms in early-stage breast cancer publication-title: J Clin Oncol doi: 10.1200/JCO.2011.38.0261 – volume: 21 start-page: 602 issue: 4 year: 2003 end-page: 606 ident: CR23 article-title: Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer publication-title: J Clin Oncol doi: 10.1200/JCO.2003.07.071 – ident: CR82 – volume: 111 start-page: 365 year: 2008 end-page: 372 ident: CR59 article-title: Prospective characterization of musculoskeletal symptoms in early stage breast cancer patients treated with aromatase inhibitors publication-title: Breast Cancer Res Treat doi: 10.1007/s10549-007-9774-6 – volume: 14 start-page: 704 year: 2005 end-page: 717 ident: CR68 article-title: Taking charge: a self-management program for women following breast cancer treatment publication-title: Psycho-Oncology doi: 10.1002/pon.891 – volume: 71 start-page: 1 year: 2006 end-page: 9 ident: CR13 article-title: Adherence to endocrine therapy for breast cancer publication-title: Oncol – volume: 19 start-page: 322 issue: 2 year: 2001 end-page: 328 ident: CR33 article-title: Adjuvant tamoxifen: predictors of use, side effects, and discontinuation in older women publication-title: J Clin Oncol – volume: 18 start-page: 78 year: 2009 end-page: 83 ident: CR38 article-title: Initial treatment and changes in adjuvant endocrine therapy for early stage breast cancer publication-title: Breast doi: 10.1016/j.breast.2009.01.002 – volume: 27 start-page: 3445 issue: 21 year: 2009 end-page: 3451 ident: CR43 article-title: Adjuvant hormonal therapy use among insured, low-income women with breast cancer publication-title: J Clin Oncol doi: 10.1200/JCO.2008.19.2419 – ident: CR63 – volume: 20 start-page: 50 issue: 10 year: 2006 end-page: 54 ident: CR78 article-title: Improving adherence to endocrine therapies: the role of advanced practice nurses publication-title: Oncol – volume: 62 start-page: 1006 issue: 10 year: 2009 end-page: 1012 ident: CR19 article-title: Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement publication-title: J Clin Epidemiol doi: 10.1016/j.jclinepi.2009.06.005 – volume: 32 start-page: 280 issue: 3 year: 2011 end-page: 282 ident: CR30 article-title: Compliance to adjuvant therapy in breast cancer patients publication-title: Eur J Gynecol Oncol – volume: 100 start-page: S1618 year: 2006 ident: CR58 article-title: Aromatase inhibitors: side effects reported by 622 women publication-title: Breast Cancer Res Treat – volume: 125 start-page: 191 year: 2011 end-page: 200 ident: CR28 article-title: Predictors of non-adherence to aromatase inhibitors among commercially insured women with breast cancer publication-title: Breast Cancer Res Treat doi: 10.1007/s10549-010-0952-6 – volume: 10 start-page: 3 issue: 1 year: 2007 end-page: 12 ident: CR22 article-title: A checklist for medication compliance and persistence studies using retrospective databases publication-title: Value Health doi: 10.1111/j.1524-4733.2006.00139.x – ident: CR48 – volume: 365 start-page: 60 year: 2005 end-page: 62 ident: CR2 article-title: Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years’ adjuvant treatment for breast cancer publication-title: Lancet doi: 10.1016/S0140-6736(04)17666-6 – volume: 73 start-page: 156 year: 2010 end-page: 166 ident: CR14 article-title: Improving compliance and persistence to adjuvant tamoxifen and aromatase inhibitor therapy publication-title: Critic Rev Oncol Hematol doi: 10.1016/j.critrevonc.2009.02.001 – volume: 59 start-page: 97 year: 2005 end-page: 102 ident: CR24 article-title: Adherence beliefs among breast cancer patients taking tamoxifen publication-title: Patient Educ Couns doi: 10.1016/j.pec.2004.10.005 – volume: 349 start-page: 1793 year: 2003 end-page: 1802 ident: CR4 article-title: A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer publication-title: N Eng J Med doi: 10.1056/NEJMoa032312 – volume: 130 start-page: 681 year: 2011 end-page: 689 ident: CR46 article-title: Five-year patterns of adjuvant hormonal therapy use, persistence, and adherence among insured women with early-stage breast cancer publication-title: Breast Cancer Res Treat doi: 10.1007/s10549-011-1703-z – volume: 12 start-page: 213 issue: 2 year: 2008 end-page: 221 ident: CR77 article-title: Adherence to endocrine therapy for breast cancer: a nursing perspective publication-title: Clin J Oncol Nurs doi: 10.1188/08.CJON.213-221 – volume: 131 start-page: 607 year: 2012 end-page: 617 ident: CR81 article-title: Racial/ethnic differences in initiation of adjuvant hormonal therapy among women with hormone receptor-positive breast cancer publication-title: Breast Cancer Res Treat doi: 10.1007/s10549-011-1762-1 – volume: 29 start-page: 2534 issue: 18 year: 2011 end-page: 2542 ident: CR44 article-title: Association between prescription co-payment amount and compliance with adjuvant hormonal therapy in women with early-stage breast cancer publication-title: J Clin Oncol doi: 10.1200/JCO.2010.33.3179 – volume: 196 start-page: 500 year: 2008 end-page: 504 ident: CR25 article-title: Noncompliance with adjuvant radiation, chemotherapy, or hormonal therapy in breast cancer patients publication-title: Am J Surg doi: 10.1016/j.amjsurg.2008.06.027 – volume: 166 start-page: 1453 year: 2006 end-page: 1465 ident: CR65 article-title: Complementary and alternative therapies for the management of menopause-related symptoms: a systematic evidence review publication-title: Arch Intern Med doi: 10.1001/archinte.166.14.1453 – volume: 28 start-page: 2423 issue: 14 year: 2010 end-page: 2429 ident: CR10 article-title: Effect of concomitant CYP2D6 inhibitor use and tamoxifen adherence on breast cancer recurrence in early-stage breast cancer publication-title: J Clin Oncol doi: 10.1200/JCO.2009.25.0894 – volume: 351 start-page: 1451 year: 1998 end-page: 1467 ident: CR20 article-title: Tamoxifen for early breast cancer: an overview of randomized trials publication-title: Lancet doi: 10.1016/S0140-6736(97)11423-4 – ident: CR7 – volume: 13 start-page: 309 year: 2012 end-page: 318 ident: CR74 article-title: Cognitive behavioral treatment for women who have menopausal symptoms after breast cancer treatment (MENOS 1): a randomised controlled trial publication-title: Lancet Oncol doi: 10.1016/S1470-2045(11)70364-3 – volume: 4 start-page: 1360 year: 2011 end-page: 1365 ident: CR52 article-title: Predicting adherence to tamoxifen for breast cancer adjuvant therapy and prevention publication-title: Cancer Prev Res doi: 10.1158/1940-6207.CAPR-11-0380 – volume: 92 start-page: 1054 issue: 13 year: 2000 end-page: 1064 ident: CR70 article-title: Managing menopausal symptoms in breast cancer survivors: results of a randomized controlled trial publication-title: J Natl Cancer Inst doi: 10.1093/jnci/92.13.1054 – volume: 22 start-page: 56 issue: 1 year: 2010 end-page: 60 ident: CR75 article-title: Managing the toxicities of aromatase inhibitors publication-title: Curr Opin Obstet Gynecol doi: 10.1097/GCO.0b013e328334e44e – volume: 295 start-page: 2057 issue: 17 year: 2006 end-page: 2071 ident: CR66 article-title: Nonhomronal therapies for menopausal hot f35es: systematic review and meta-analysis publication-title: J Am Med Assoc doi: 10.1001/jama.295.17.2057 – volume: 17 start-page: 55 year: 2012 end-page: 63 ident: CR12 article-title: Age-specific nonpersistence of endocrine therapy in postmenopausal patients diagnosed with hormone receptor-positive breast cancer: a TEAM study analysis publication-title: Oncologist doi: 10.1634/theoncologist.2011-0037 – volume: 9 start-page: 258 issue: 4 year: 2009 end-page: 264 ident: CR39 article-title: Cytochrome P450 2D6 activity predicts discontinuation of tamoxifen therapy in breast cancer patients publication-title: Pharmacogenomics doi: 10.1038/tpj.2009.14 – volume: 10 start-page: 3 issue: 1 year: 2007 ident: 2114_CR22 publication-title: Value Health doi: 10.1111/j.1524-4733.2006.00139.x – volume: 99 start-page: 215 year: 2006 ident: 2114_CR35 publication-title: Breast Cancer Res Treat doi: 10.1007/s10549-006-9193-0 – ident: 2114_CR64 doi: 10.1097/NCC.0b013e31824a7e18 – volume: 22 start-page: 3309 issue: 16 year: 2004 ident: 2114_CR34 publication-title: J Clin Oncol doi: 10.1200/JCO.2004.11.064 – volume: 133 start-page: 367 year: 2012 ident: 2114_CR32 publication-title: Breast Cancer Res Treat doi: 10.1007/s10549-012-1961-4 – volume: 351 start-page: 1451 year: 1998 ident: 2114_CR20 publication-title: Lancet doi: 10.1016/S0140-6736(97)11423-4 – volume: 32 start-page: 280 issue: 3 year: 2011 ident: 2114_CR30 publication-title: Eur J Gynecol Oncol – volume: 9 start-page: 258 issue: 4 year: 2009 ident: 2114_CR39 publication-title: Pharmacogenomics doi: 10.1038/tpj.2009.14 – ident: 2114_CR49 – volume: 196 start-page: 500 year: 2008 ident: 2114_CR25 publication-title: Am J Surg doi: 10.1016/j.amjsurg.2008.06.027 – volume: 17 start-page: 227 issue: 3 year: 2008 ident: 2114_CR76 publication-title: Breast doi: 10.1016/j.breast.2007.11.001 – volume: 4 start-page: 1360 year: 2011 ident: 2114_CR52 publication-title: Cancer Prev Res doi: 10.1158/1940-6207.CAPR-11-0380 – volume: 9 start-page: 45 year: 2008 ident: 2114_CR3 publication-title: Lancet Oncol doi: 10.1016/S1470-2045(07)70385-6 – volume: 14 start-page: 704 year: 2005 ident: 2114_CR68 publication-title: Psycho-Oncology doi: 10.1002/pon.891 – volume: 13 start-page: 309 year: 2012 ident: 2114_CR74 publication-title: Lancet Oncol doi: 10.1016/S1470-2045(11)70364-3 – volume: 28 start-page: 4120 issue: 27 year: 2010 ident: 2114_CR83 publication-title: J Clin Oncol doi: 10.1200/JCO.2009.25.9655 – volume: 19 start-page: 322 issue: 2 year: 2001 ident: 2114_CR33 publication-title: J Clin Oncol doi: 10.1200/JCO.2001.19.2.322 – volume: 122 start-page: 843 year: 2010 ident: 2114_CR40 publication-title: Breast Cancer Res Treat doi: 10.1007/s10549-009-0724-3 – volume: 34 start-page: 1007 issue: 5 year: 2007 ident: 2114_CR72 publication-title: Oncol Nurs Forum doi: 10.1188/07.ONF.1007-1016 – volume: 26 start-page: 549 issue: 4 year: 2008 ident: 2114_CR37 publication-title: J Clin Oncol doi: 10.1200/JCO.2006.10.1022 – ident: 2114_CR53 doi: 10.1007/s10549-012-2066-9 – volume: 96 start-page: 376 issue: 5 year: 2004 ident: 2114_CR69 publication-title: J Natl Cancer Inst doi: 10.1093/jnci/djh060 – volume: 73 start-page: 156 year: 2010 ident: 2114_CR14 publication-title: Critic Rev Oncol Hematol doi: 10.1016/j.critrevonc.2009.02.001 – volume: 129 start-page: 299 year: 2011 ident: 2114_CR15 publication-title: Breast Cancer Res Treat doi: 10.1007/s10549-011-1578-z – volume: 1 start-page: E1 issue: 4 year: 2011 ident: 2114_CR31 publication-title: Medicare Medicaid Res Rev doi: 10.5600/mmrr.001.04.a04 – volume: 129 start-page: 799 year: 2011 ident: 2114_CR41 publication-title: Breast Cancer Res Treat doi: 10.1007/s10549-011-1668-y – volume: 92 start-page: 1054 issue: 13 year: 2000 ident: 2114_CR70 publication-title: J Natl Cancer Inst doi: 10.1093/jnci/92.13.1054 – volume: 21 start-page: 10 year: 2012 ident: 2114_CR18 publication-title: Eur J Cancer Care doi: 10.1111/j.1365-2354.2011.01295.x – volume: 59 start-page: 56 year: 2009 ident: 2114_CR21 publication-title: CA Cancer J Clin doi: 10.3322/caac.20004 – volume: 59 start-page: 97 year: 2005 ident: 2114_CR24 publication-title: Patient Educ Couns doi: 10.1016/j.pec.2004.10.005 – volume: 62 start-page: 1006 issue: 10 year: 2009 ident: 2114_CR19 publication-title: J Clin Epidemiol doi: 10.1016/j.jclinepi.2009.06.005 – volume: 111 start-page: 365 year: 2008 ident: 2114_CR59 publication-title: Breast Cancer Res Treat doi: 10.1007/s10549-007-9774-6 – volume: 19 start-page: 472 year: 2010 ident: 2114_CR61 publication-title: Pyscho-Oncology doi: 10.1002/pon.1593 – volume: 378 start-page: 771 year: 2011 ident: 2114_CR6 publication-title: Lancet doi: 10.1016/S0140-6736(11)60993-8 – volume: 104 start-page: 1558 year: 2011 ident: 2114_CR45 publication-title: Br J Cancer doi: 10.1038/bjc.2011.140 – ident: 2114_CR63 doi: 10.3109/13697137.2011.620658 – volume: 45 start-page: 431 issue: 5 year: 2007 ident: 2114_CR36 publication-title: Med Care doi: 10.1097/01.mlr.0000257193.10760.7f – volume: 23 start-page: 882 year: 2012 ident: 2114_CR54 publication-title: Ann Oncol doi: 10.1093/annonc/mdr330 – volume: 26 start-page: 1403 issue: 12 year: 2011 ident: 2114_CR51 publication-title: J Gen Intern Med doi: 10.1007/s11606-011-1808-4 – volume: 295 start-page: 2057 issue: 17 year: 2006 ident: 2114_CR66 publication-title: J Am Med Assoc doi: 10.1001/jama.295.17.2057 – volume: 125 start-page: 279 year: 2011 ident: 2114_CR29 publication-title: Breast Cancer Res Treat doi: 10.1007/s10549-010-1139-x – volume: 18 start-page: S3 issue: Suppl 1 year: 2011 ident: 2114_CR17 publication-title: Curr Oncol doi: 10.3747/co.v18i0.899 – volume: 28 start-page: 2423 issue: 14 year: 2010 ident: 2114_CR10 publication-title: J Clin Oncol doi: 10.1200/JCO.2009.25.0894 – volume: 11 start-page: 709 issue: 6 year: 2011 ident: 2114_CR16 publication-title: Expert Rev Pharmacoeconomics Outcomes Res doi: 10.1586/erp.11.80 – volume: 192 start-page: 496 year: 2006 ident: 2114_CR55 publication-title: Am J Surg doi: 10.1016/j.amjsurg.2006.06.018 – volume: 126 start-page: 529 year: 2011 ident: 2114_CR11 publication-title: Breast Cancer Res Treat doi: 10.1007/s10549-010-1132-4 – volume: 66 start-page: 73 year: 2001 ident: 2114_CR57 publication-title: Breast Cancer Res Treat doi: 10.1023/A:1010684903199 – volume: 166 start-page: 1453 year: 2006 ident: 2114_CR65 publication-title: Arch Intern Med doi: 10.1001/archinte.166.14.1453 – volume: 22 start-page: 56 issue: 1 year: 2010 ident: 2114_CR75 publication-title: Curr Opin Obstet Gynecol doi: 10.1097/GCO.0b013e328334e44e – volume: 6 start-page: 221 issue: 3 year: 2011 ident: 2114_CR79 publication-title: Breast Care doi: 10.1159/000329006 – ident: 2114_CR82 – volume: 26 start-page: 556 issue: 4 year: 2008 ident: 2114_CR42 publication-title: J Clin Oncol doi: 10.1200/JCO.2007.11.5451 – volume: 125 start-page: 191 year: 2011 ident: 2114_CR28 publication-title: Breast Cancer Res Treat doi: 10.1007/s10549-010-0952-6 – ident: 2114_CR47 doi: 10.1097/COC.0b013e3182436ec1 – volume: 6 start-page: 687 year: 2005 ident: 2114_CR67 publication-title: Lancet Oncol doi: 10.1016/S1470-2045(05)70316-8 – volume: 88 start-page: 1529 year: 1996 ident: 2114_CR1 publication-title: J Natl Cancer Inst doi: 10.1093/jnci/88.21.1529 – volume: 71 start-page: 1 year: 2006 ident: 2114_CR13 publication-title: Oncol doi: 10.1159/000100444 – volume: 21 start-page: 602 issue: 4 year: 2003 ident: 2114_CR23 publication-title: J Clin Oncol doi: 10.1200/JCO.2003.07.071 – volume: 99 start-page: 428 year: 2008 ident: 2114_CR26 publication-title: Br J Cancer doi: 10.1038/sj.bjc.6604525 – volume: 20 start-page: 50 issue: 10 year: 2006 ident: 2114_CR78 publication-title: Oncol – volume: 131 start-page: 607 year: 2012 ident: 2114_CR81 publication-title: Breast Cancer Res Treat doi: 10.1007/s10549-011-1762-1 – volume: 365 start-page: 60 year: 2005 ident: 2114_CR2 publication-title: Lancet doi: 10.1016/S0140-6736(04)17666-6 – volume: 350 start-page: 1081 year: 2004 ident: 2114_CR5 publication-title: N Engl J Med doi: 10.1056/NEJMoa040331 – volume: 27 start-page: 3445 issue: 21 year: 2009 ident: 2114_CR43 publication-title: J Clin Oncol doi: 10.1200/JCO.2008.19.2419 – volume: 18 start-page: 78 year: 2009 ident: 2114_CR38 publication-title: Breast doi: 10.1016/j.breast.2009.01.002 – volume: 349 start-page: 1793 year: 2003 ident: 2114_CR4 publication-title: N Eng J Med doi: 10.1056/NEJMoa032312 – volume: 14 start-page: 962 year: 2005 ident: 2114_CR73 publication-title: Psycho-Oncology doi: 10.1002/pon.909 – volume: 7 start-page: 775 issue: 10 year: 2007 ident: 2114_CR60 publication-title: Clin Breast Cancer doi: 10.3816/CBC.2007.n.038 – volume: 17 start-page: 55 year: 2012 ident: 2114_CR12 publication-title: Oncologist doi: 10.1634/theoncologist.2011-0037 – volume: 12 start-page: 213 issue: 2 year: 2008 ident: 2114_CR77 publication-title: Clin J Oncol Nurs doi: 10.1188/08.CJON.213-221 – volume: 30 start-page: 142 issue: 2 year: 2012 ident: 2114_CR80 publication-title: J Clin Oncol doi: 10.1200/JCO.2011.36.8399 – volume: 99 start-page: 1763 year: 2008 ident: 2114_CR9 publication-title: Br J Cancer doi: 10.1038/sj.bjc.6604758 – volume: 29 start-page: 2534 issue: 18 year: 2011 ident: 2114_CR44 publication-title: J Clin Oncol doi: 10.1200/JCO.2010.33.3179 – volume: 30 start-page: 936 issue: 9 year: 2012 ident: 2114_CR62 publication-title: J Clin Oncol doi: 10.1200/JCO.2011.38.0261 – volume: 18 start-page: 560 year: 2009 ident: 2114_CR71 publication-title: Psycho-Oncology doi: 10.1002/pon.1414 – volume: 20 start-page: 431 year: 2009 ident: 2114_CR27 publication-title: Ann Oncol doi: 10.1093/annonc/mdn646 – volume: 107 start-page: 167 year: 2008 ident: 2114_CR56 publication-title: Breast Cancer Res Treat doi: 10.1007/s10549-007-9548-1 – volume: 6 start-page: 243 issue: 5 year: 2010 ident: 2114_CR8 publication-title: J Oncol Pract doi: 10.1200/JOP.000082 – volume: 100 start-page: S1618 year: 2006 ident: 2114_CR58 publication-title: Breast Cancer Res Treat – ident: 2114_CR50 – ident: 2114_CR48 doi: 10.1016/j.ejca.2012.03.004 – ident: 2114_CR7 – volume: 130 start-page: 681 year: 2011 ident: 2114_CR46 publication-title: Breast Cancer Res Treat doi: 10.1007/s10549-011-1703-z – reference: 23400580 - Breast Cancer Res Treat. 2013 Feb;138(1):325-8. doi: 10.1007/s10549-013-2422-4. |
| SSID | ssj0009709 |
| Score | 2.5721238 |
| SecondaryResourceType | review_article |
| Snippet | Adjuvant hormonal therapy significantly improves long-term survival of breast cancer patients with hormone receptor-positive disease. Despite the proven... |
| SourceID | pubmedcentral proquest gale pubmed pascalfrancis crossref springer |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 459 |
| SubjectTerms | Adjuvant treatment Antineoplastic Agents, Hormonal - therapeutic use Biological and medical sciences Breast cancer Breast Neoplasms - drug therapy Breast Neoplasms - mortality Cancer Cancer research Cancer survivors Cancer therapies Care and treatment Chemotherapy, Adjuvant Clinical Trials as Topic Cytochrome P-450 Endocrine therapy Female Gynecology. Andrology. Obstetrics Health aspects Health behavior Humans Mammary gland diseases Medical sciences Medication Adherence Medicine Medicine & Public Health Neoplasms, Hormone-Dependent - drug therapy Neoplasms, Hormone-Dependent - mortality Oncology Patient compliance Review Survivors Systematic review Tamoxifen Tumors |
| SummonAdditionalLinks | – databaseName: Health & Medical Collection dbid: 7X7 link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9QwELagIFQJ8W4JlGIkJCSqiDztmAtaISouVBxA2pvlOLZ2EUq2m2yl_vvOxE5CePTC2ZPEiT-PP8cz3xDymjGlImuqkMNiAxuUQoSlKVTIRF5oLQQvddUXm-BnZ8VyKb76H26tD6scfGLvqKtG4z_yd3HP3bmI8w-b8xCrRuHpqi-hcZPcwrLZiHO-5JPoLnchHqjtzYqIDaeaLnUOdkawkU5C2AJlYT5bl7x3vrtRLXwp60pc_I2D_hlK-dt5ar9Mnd7_3xd8QO55gkoXDlEPyQ1TPyJ3vvgj-MekXlQrlyJIu4aq6scOuHhHV8B9kdRTl9B1SfsqRrTEmPeOasTWlrY7cEwXzbal65oOOZl0SNR6TxWdhKWpS6p5Qr6ffvr28XPoizaEmrGsC40wqPqmuYWdoC55XIJP5CYzUW65VbGNDToWYEaWoxaiFih3I0QSq8SyKkoPyF7d1OYpobj1ihm6HZFnZRWpLC-sTbMUwGSqPA1INAyZ1F7RHAtr_JSTFjOOsoRRljjKMg_I2_GSjZPzuM74JeJAuozU0RXIRZoDi-RJxgLyprdAZwBP1srnNED_UVZrZnk0s4RJrGfNxzOsjZ3DegHA2iK4fkCN9F6mlRNkAvJqbMZbY-RcbZod2iQcCAlDm0OH1enmCSsEEMaA8BmKRwPUHp-31OtVr0GesognBfT7ZMD7r936xwd9dv1LPCf7CU7IPhj6iOx12515QW7ri27dbo_7qX0FJ2VS2w priority: 102 providerName: ProQuest |
| Title | Adherence to adjuvant hormonal therapy among breast cancer survivors in clinical practice: a systematic review |
| URI | https://link.springer.com/article/10.1007/s10549-012-2114-5 https://www.ncbi.nlm.nih.gov/pubmed/22689091 https://www.proquest.com/docview/1030117915 https://www.proquest.com/docview/1027678615 https://pubmed.ncbi.nlm.nih.gov/PMC3607286 |
| Volume | 134 |
| WOSCitedRecordID | wos000306730500002&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVPQU databaseName: Consumer Health Database customDbUrl: eissn: 1573-7217 dateEnd: 20171231 omitProxy: false ssIdentifier: ssj0009709 issn: 0167-6806 databaseCode: M0R dateStart: 19970101 isFulltext: true titleUrlDefault: https://search.proquest.com/familyhealth providerName: ProQuest – providerCode: PRVPQU databaseName: Health & Medical Collection customDbUrl: eissn: 1573-7217 dateEnd: 20171231 omitProxy: false ssIdentifier: ssj0009709 issn: 0167-6806 databaseCode: 7X7 dateStart: 19970101 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: eissn: 1573-7217 dateEnd: 20171231 omitProxy: false ssIdentifier: ssj0009709 issn: 0167-6806 databaseCode: BENPR dateStart: 19970101 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVPQU databaseName: Public Health Database customDbUrl: eissn: 1573-7217 dateEnd: 20171231 omitProxy: false ssIdentifier: ssj0009709 issn: 0167-6806 databaseCode: 8C1 dateStart: 19970101 isFulltext: true titleUrlDefault: https://search.proquest.com/publichealth providerName: ProQuest – providerCode: PRVPQU databaseName: Research Library customDbUrl: eissn: 1573-7217 dateEnd: 20171231 omitProxy: false ssIdentifier: ssj0009709 issn: 0167-6806 databaseCode: M2O dateStart: 19970101 isFulltext: true titleUrlDefault: https://search.proquest.com/pqrl providerName: ProQuest – providerCode: PRVAVX databaseName: SpringerLINK Contemporary 1997-Present customDbUrl: eissn: 1573-7217 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0009709 issn: 0167-6806 databaseCode: RSV dateStart: 19970101 isFulltext: true titleUrlDefault: https://link.springer.com/search?facet-content-type=%22Journal%22 providerName: Springer Nature |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3ra9RAEB9sK1IQ39bTeq4gCJZAnvvw21la_NKz-OK-hc1mlzuRXLnkCv73zmySu0aroF8Wjp3sTSazszPszG8AXnGudehsGQg8bDBAkSoorNQBV5k0RilRmNI3mxDTqZzN1HlXx1332e79laS31FeK3TCWwdA3DjBoSYNsB_YyApuhEP3T1y3SrmjzOgjQm8uQ91eZ1y0xOIw6k3z7QtcoHtf2tbjO8fw9f_KXS1R_Np3e_a-3ugd3OleUTVrduQ83bPUAbp11l-0PoZqU87YYkDVLpstva_S6GzZHL5fcd9aWbv1gvl8RKyi7vWGGtGjF6jWaoMvlqmaLivXVl6wvyXrLNNtCSLO2fOYRfDk9-Xz8PujaMwSG87QJrLKE72aEw5jPFCIq0PoJm9owc8LpyEWWTAj6QE4Q6qFRBGyjVBzp2PEyTB7DbrWs7BNgFGRFnAyMytKiDHWaSeeSNEG1sWWWjCDsv1NuOuxyaqHxPd-iLpMcc5RjTnLMsxG82Txy0QJ3_I34BX38vK093Wz6fJJk6C-KOOUjeO0paNvjPxvdVS8g_wSgNaA8HFDidjWD6fFAwTbMUWcA9M9CfL7XuLyzJ3Ue-chVqAhZfbmZpqUpR66yyzXRxAJdD040B62CbhePuVToGo5ADFR3Q0Ao48OZajH3aOMJD0Uske-jXoGvsvUHgT79J-pnsB_TDvBZ0Iew26zW9jncNJfNol6NYUfMhB8ljvI4GsPeu5Pp-Uf8dRb6Mf4w9kbgJzd3Tnw |
| linkProvider | Springer Nature |
| linkToHtml | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Lb9QwEB6VggAJ8X4slNZIoEqgiMRJ7BgJoVWhatV2xaFIvYXEcbSLUHbZZIv6p_iNzMR5EB699cDZE8dJZj7PxDPfADwXIknc3GSOxM0GA5RIOamJEkeoMNJaKZnqrG42ISeT6OREfVyDH20tDKVVtphYA3U21_SP_LVX--5SeeG7xTeHukbR6WrbQsOqxYE5-44hW_l2_z1-3xec73443tlzmq4CjhYiqByjDNGSaZljqKJT6aVotNIExg1zmSde7hnSfNy6c0lkfVoRH4tS3Et4LjLXx3kvweXA5z5ZUbTTp5QoaVNKiEtcRK5oT1FtqR7eFAN37mDIFTjhYB9sdoMbi6TEL5Pblhp_83n_TN387fy23hZ3b_1vL_Q23GwccDa2FnMH1kxxF64eNSkG96AYZ1NbAsmqOUuyLyuMNSo2Rd-eghZmC9bOWN2liaWU018xTbazZOUKgfd0vizZrGBtzSlrC9HesIT1xNnMFg3dh08X8rQPYL2YF-YRMAotPUGwqsIgzdwkCKM89wMfjcVkoT8Ct1WRWDeM7dQ45Gvcc02TVsWoVTFpVRyO4GV3ycLSlZwnvEV6F9uK2w7q4rEfopcseSBGsF1LENjhnXXS1Gzg-ok2bCC5MZBEkNKD4c2BbneLo34I6JW6eH2rpXGDomXcq-gInnXDNDVlBhZmviIZLtHhEiTz0NpGPzkXkUKHeARyYDWdAHGrD0eK2bTmWPeFK3mE637V2tevy_rHC318_kNswbW946PD-HB_cvAErnMCgzrxewPWq-XKPIUr-rSalcvNGlYYfL5os_sJWqaspA |
| linkToPdf | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1ta9RAEB7qVYogvr-c1nYFRVBC87qbFURO28NSPQ6x0G8x2exyJ5I7L7lK_5q_zplscmd86bd-8PNONptk5tmZ7MwzAE84T1PX6NwRuNlggBJLJ9Nx6nAZxUpJKTKV180mxGgUn5zI8Qb8aGthKK2yxcQaqPOZon_ke17tuwvpRXumSYsY7w9fz7851EGKTlrbdhpWRY702XcM38pXh_v4rZ_6_vDg09t3TtNhwFGch5WjpSaKMiUMhi0qE16GBix0qN3ICJN6xtNkBbiNG0HEfUoSN4uUvpf6hudugPNegk0RYNDTg803B6PxxzXlr7AJJsQszmOXt2eqtnAPb4thvO9gABY6UWdXbPaGq_O0xO9kbIONv3nAfyZy_naaW2-Sw-v_8-u9Adca15wNrC3dhA1d3IKtD03ywW0oBvnEFkeyasbS_MsSo5CKTdDrp3CG2VK2M1b3b2IZZftXTJFVLVi5REg-nS1KNi1YW43K2hK1lyxla0ptZsuJ7sDxhTztXegVs0LfB0ZBp8cJcGUUZrmbhlFsTBAGaEY6j4I-uK26JKrhcqeWIl-TNQs1aViCGpaQhiVRH56vLplbIpPzhHdJBxNbi7sCwWQQROg_Cz_kfXhWSxAM4p1V2lRz4PqJUKwjud2RRPhSneGdjp6vFkedEtBfdfH6VmOTBl_LZK2ufXi8GqapKWew0LMlyfgCXTFOMvesnawn93ks0VXug-hY0EqAWNe7I8V0UrOvB9wVfozrftHa2q_L-scLfXD-Q-zCFlpb8v5wdPQQrviEC3VG-Db0qsVSP4LL6rSaloudBmMYfL5ou_sJOYG3Ag |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Adherence+to+adjuvant+hormonal+therapy+among+breast+cancer+survivors+in+clinical+practice%3A+a+systematic+review&rft.jtitle=Breast+cancer+research+and+treatment&rft.au=Murphy%2C+Caitlin+C&rft.au=Bartholomew%2C+L+Kay&rft.au=Carpentier%2C+Melissa+Y&rft.au=Bluethmann%2C+Shirley+M&rft.date=2012-07-01&rft.issn=1573-7217&rft.eissn=1573-7217&rft.volume=134&rft.issue=2&rft.spage=459&rft_id=info:doi/10.1007%2Fs10549-012-2114-5&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0167-6806&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0167-6806&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0167-6806&client=summon |